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This study mainly focused on identifying the role of transcription factors such 
as Runx1t1 and PPARγ, in modulating the activation of microglia in 
neuropathologies and on elucidating the mechanism of action and therapeutic 
potential of costunolide, a herbal compound on the inflammatory reactions of 
activated microglia after traumatic brain injury (TBI). 
Runx1t1 (runt-related transcription factor 1; translocated to, 1) 
epigenetically regulates the proliferation and nitric oxide production of 
microglia 
Microglia, the resident immune cells of the brain, undergo rapid proliferation 
and produce several proinflammatory molecules and nitric oxide (NO) when 
activated in neuropathological conditions. Runx1t1 (Runt-related transcription 
factor 1, translocated to 1), a member of Runx family has been implicated in 
recruiting histone deacetylases (HDACs) for transcriptional repression, 
thereby regulating cell proliferation. In the present study, Runx1t1 expression 
was localized in amoeboid microglial cells of the postnatal rat brain, and 
hardly detectable in ramified microglia of the adult brain. Moreover, the 
Runx1t1protein expression was induced and translocated to nuclei in activated 
microglia in vitro and in vivo. In view of these findings, it was hypothesized 
that Runx1t1 regulates microglial functions during development and in 
neuropathological conditions. siRNA-mediated knockdown of Runx1t1 in 
activated BV2 microglia significantly decreased the expression level of cell 
cycle-related gene, cyclin-dependent kinase 4 (Cdk4) and proliferation index. 




of Runx1t1 knockdown on microglial proliferation, confirming that microglial 
proliferation is associated with Runx1t1 expression and HDACs activity.  
    Further, Runx1t1 and HDACs were shown to promote neurotoxic 
effect of microglia by repressing the expression of LAT2, L-aminoacid 
transporter-2 (cationic amino acid transporter, y+ system), which normally 
inhibits NO production. This was confirmed by chromatin 
immunoprecipitation (ChIP) assay, which revealed that Runx1t1 binds to the 
promoter region of LAT2 and this binding increased upon microglial 
activation. However, the enhanced binding of Runx1t1 to the LAT2 promoter 
could not repress LAT2 expression when BV2 microglial cells were treated 
with HDACi, indicating that Runx1t1 requires HDACs to transcriptionally 
repress the expression of LAT2. In conclusion, it is suggested that Runx1t1 
controls proliferation and the neurotoxic effect of microglia by epigenetically 
regulating Cdk4 and LAT2 via its interaction with HDACs. 
 
Costunolide inhibits microglia-mediated neuroinflammation in traumatic 
brain injury (TBI) by binding with PPARγ receptor 
TBI causes irreversible damage to the brain resulting in neurological 
impairments. Microglia, the resident macrophages in the central nervous 
system (CNS) mediate the inflammatory reaction in a number of neurological 
disorders including TBI. Activation of microglial cells upon brain injury 
triggers the release of pro-inflammatory cytokines, chemokines, reactive 
oxygen species (ROS) and NO that augment neuroinflammation and 
subsequent neurodegeneration in the CNS. Therefore, identifying potential 




may help development of effective therapeutic interventions for TBI-related 
neurological complications. 
 We have shown that costunolide has anti-inflammatory properties and 
inhibits the activation of murine BV2 microglia (Rayan et al., 2011). The 
current study focused on evaluating the therapeutic potential and mechanism 
of action of costunolide, on the activation and inflammatory response of 
microglia post-TBI. It has been shown that TBI induced the proliferation of 
microglia in the CA1 region of hippocampus and the costunolide treatment 
controlled the accumulation of activated microglia in the hippocampus post-
TBI. Further it has been observed that costunolide mediates the inhibition of 
MAPK-NFκB proinflammatory pathway in activated microglia of rats post-
TBI.  
 In silico analysis via molecular docking mechanism has identified that 
costunolide binds with PPARγ receptor, which is a ligand-activated 
transcription factors belonging to the class of nuclear receptors. PPARγ has 
been shown to regulate inflammatory response of the microglia in the brain. 
This interaction between costunolide and PPARγ receptor was confirmed by in 
vivo analysis, which showed that costunolide treatment induces PPARγ 
nuclear expression in activated microglia post-TBI. In vitro studies have also 
demonstrated that costunolide treatment induces PPARγ nuclear expression in 
LPS-activated BV2 microglia.  
There is mounting evidence that the PPARγ ligands repress the 
expression of several inflammatory response genes including TNFα, IL-6, IL-
1β and inducible NO synthase (iNOS). Costunolide mediates a similar 




activated BV2 microglia (Rayan et al. 2011). The present study also showed 
that costunolide treatment induces PPARγ expression in activated microglia 
post-TBI, indicating that costunolide inhibits the pro-inflammatory response 
of microglia through PPARγ receptor. This also provided experimental 
validation to the in silico prediction of costunolide as an agonist to PPARγ. 
Further, this PPARγ-Costunolide interaction has been validated in vitro by 
overexpressing dominant negative (DN) PPARγ in BV2 microglia. 
Costunolide treatment could not inhibit the activation of BV2 microglia 
following overexpression of DN- PPARγ as it inhibits the functional activity 
of endogenous PPARγ in BV2 microglia.  
It was also observed that costunolide treatment to activated microglial 
cells markedly reduced Runx1t1 expression both in vivo and in vitro. This 
finding is interesting as Runx1t1 appears to control microglial activation and 
proliferation in neuropathologies. However, the mechanism by which 
costunolide acts on Runx1t1 is not clear. One of the possible mechanisms by 
which costunolide exerts its inhibitory effect on Runx1t1 is by activating 
PPARγ.  
 Overall, this study demonstrated that costunolide modulates microglial 
activation by binding with PPARγ receptor. Thus the interaction of 
costunolide and PPARγ signaling in microglia may be considered for a 






























The central nervous system (CNS) mainly consists of two types of cells, 
neurons and glial cells including astrocytes, oligodendrocytes and microglia in 
its parenchyma (Kandel et al. 2000). In general, there are three types of 
neurons: 1. Sensory neurons, which transmit sensory information from the 
sensory organs to the CNS; 2. Motor neurons, which transmit information and 
commands to the target tissue from the CNS; 3. Interneurons, which facilitate 
communication between the sensory and motor neurons (Kandel et al. 2000). 
Glial cells support and maintain these neurons. Oligodendrocytes produce 
insulating protein, myelin which wraps around the axons of neurons for faster 
neurotransmission, while astrocytes provide neurons with nutrition and 
support them (Baumann & Pham-Dinh 2001, Perea et al. 2009, Araque et al. 
1999). Microglia are considered to be the resident immuno-competent cells of 
the CNS. The neurons and glia in the brain parenchyma are affected by 
various changes including ageing, trauma, infection, tumors, inflammation and 
neurodegenration (Mills et al. 2010, Morrison & Hof 1997, Farfara et al. 
2008, Singh et al. 2004). The response of these cells to a range of 
neuropathological conditions has been widely studied.  In this study, the 
signaling pathways that regulate functions of microglia have been investigated 
as the microglia are essential for proper brain functions and are relatively less 
explored.  
Microglia constitute about 5-12% of the total glial cell population and 
are the key cellular mediators of neuroinflammation (Ling & Leblond 1973, 
Kaur et al. 2001, Figuera-Losada et al. 2013, Sarma 2013, Dheen et al. 2007). 
Microglial cells respond to various stimuli in the CNS and become activated. 




agents by phagocytosis, thus functions as brain macrophages. However, 
chronic activation of microglia exacerbates neuronal damage due to excessive 
release of pro-inflammatory cytokines, chemokines and other inflammatory 
mediators, which contribute to neuroinflammation and subsequent 
neurodegeneration in the CNS (Streit et al. 2004, Dheen et al. 2007).  
Microglial cells are morphologically classified into three types, 
amoeboid microglial cells (AMC), ramified or resting microglial cells (RMC) 
and activated or reactive microglial cells (Kaur et al. 2001, Kaur et al. 1985). 
AMC are found in the developing brain and function as brain macrophages 
(Kaur et al. 2001, Kaur et al. 1985, Dheen et al. 2002). The AMC transform 
into ramified microglia which make up the permanent population of microglial 
cells in the adult CNS (Kaur et al. 2001, Ling & Wong 1993, Dheen et al. 
2007). Although RMC are traditionally considered ‘resting’, recent evidence 
indicates that they constantly survey the brain parenchyma and influence 
synaptic connectivity (Tremblay et al. 2010, Nimmerjahn et al. 2005). They 
become activated upon injury, infection or other pathological conditions in the 
adult CNS. Activated microglia undergo rapid proliferation, become spherical 
in shape (amoeboid), secrete proinflammatory cytokines, chemokines, and 
growth factors and remove damaged neurons and weaker synapses by 
phagocytosis (Ling & Wong 1993, Kettenmann et al. 2013, Dheen et al. 
2007). Activated microglia serve diverse beneficial functions essential for 
neuronal survival such as release of neurotropic and anti-inflammatory factors, 
clearing of toxic cellular debris from the CNS parenchyma (Ling & Wong 
1993, Dheen et al. 2007). However, under certain circumstances microglia can 




pro-inflammatory cytokines and other neurotoxic mediators which contribute 
to neuroinflammation and subsequently neurodegeneration (Kaur et al. 1985, 
Dheen et al. 2007). 
 
1.1 Origin of Microglial cells 
Historically, microglial cells were believed to have originated from (i) 
neuroectoderm, (ii), circulating monocytes (iii) peripheral 
mesodermal/mesenchymal tissues, or (iv) primitive myeloid precursor cells of 
the yolk sac. Microglial cells were first identified in brain parenchyma in 1932 
and believed to be derived from the mononuclear cells of the circulating 
blood, indicating the non-neuroectodermal origin (del Río Hortega 1932). 
Later, it was shown that the precursor cells of monocyte-macrophage lineage 
or the circulating monocytes enter brain during the embryonic, fetal or 
postnatal stages of development and differentiate to form microglia (Ling & 
Wong 1993, Kaur et al. 2001, Ling & Leblond 1973, Kaur et al. 1984). 
Recently in vivo lineage study revealed that microglia are derived from the 
primitive myeloid precursors or progenitors originating from the extra 
embryonic yolk sac. These microglial precursor cells enter the nervous tissue 
through blood circulation between embryonic day 8.5 and 9.5 and  
differentiate to form microglia (Ginhoux et al. 2010). Microglial cell is the 
first cell type to develop in the fetal brain as both astrogliogenesis and 
oligodendrogliogenesis have been shown to occur later in the brain. These 





1.2 Functional dynamics of microglia  
AMC in the developing brain function as active macrophages, phagocytose the 
apoptotic cells and infectious agents and help in neuronal health and survival 
(Kaur et al. 2001, Kaur et al. 1985, Dheen et al. 2002). Further, AMC have 
been shown to promote synaptogenesis through secretion of growth factors 
and control the number of synapses by pruning weaker synapses in the 
developing brain during pre and postnatal development (Kettenmann et al. 
2013, Tremblay et al. 2010). AMC gradually transform and acquire a ramified 
morphology with several motile processes during postnatal development. The 
RMC in the adult brain maintain brain homeostasis. However, upon activation 
in pathological conditions, RMC undergo rapid morphological and functional 
changes in order to adapt or respond to the changing environment in the CNS 
(Ling & Wong 1993, Dheen et al. 2007). Activation of microglial cells is 
associated with induction of inflammatory response, altered gene expression 
and epigenetic changes in microglial cells (Ling & Wong 1993, Vilhardt 2005, 
Garden 2013). Activated microglial cells migrate to the site of injury or 
infection, where they undergo rapid proliferation and release a number of 
soluble factors including cytokines, chemokines and other inflammatory 
mediators and remove the damaged neurons or unwanted cell debris by 
phagocytosis (Dheen et al. 2007). Activated microglia release a wide range of 
growth factors, cytokines and free radicals including neurotropic factors such 
as nerve growth factor (NGF), transforming growth factor-β1 (TGF-β1), 
interleukin 3 (1L-3) and pro-inflammatory mediators such as interleukin 1β 




species (ROS) and nitric oxide (NO) (Chao et al. 1992, Colton & Gilbert 
1987, Piani et al. 1991, Taylor et al. 2005, Nakajima et al. 2007). Recent 
studies show that activated microglia exists in two different states, the 
classically activated M1 phenotype which is pro-inflammatory and 
alternatively activated M2 phenotype which is anti-inflammatory (Li et al. 
2014). Treatment with lipopolysaccharide (LPS) and interferon-ɣ (IFNɣ) 
activates microglia towards  M1 phenotype, which secretes excessive amount 
of pro-inflammatory cytokines and NO (Ding et al. 1988, Li et al. 2014). 
Treatment with interleukin-4 (IL-4) or IL-13 promotes transformation of 
microglia into M2 phenotype, which produce anti-inflammatory factors and 
help in tissue remodeling (Miron et al. 2013) 
 
1.2.1 Migration 
The migration of microglial cells to the site of injury/infection is directed by a 
process called ‘chemotaxis’ (Noda & Suzumura 2012). Chemotaxis is induced 
by chemokines, which are chemotactic cytokines that attract microglia to the 
site of injury or infection (Eugenin et al. 2005, Noda & Suzumura 2012). It 
has been reported that in Alzheimer’s disease (AD), levels of chemokines are 
increased to recruit microglia to the site of amyloid-beta (Aβ) plaques (Huang 
et al. 2010). It has been well established that ramification of microglia which 
is influenced by F-actin polymerization and tubulin filament formation 
facilitates migration (Vincent et al. 2012). Rearrangement of actin and tubulin 
filaments occur upon any chemotactic stimulus in order to facilitate 
attachment, protrusion and traction which helps in migration (Eugenin et al. 




signaling is required for neuronal-microglia interaction since, the inhibition of 
CX3CR1 signaling could reduce recruitment of peripheral macrophages and 
CNS microglia in an ischemic rodent model of stroke (Tang et al. 2014).  
 
1.2.2 Proliferation 
It has been well documented that microglial proliferation is one of the 
hallmarks of neuropathological conditions caused by infection, trauma or other 
neurological disorders in order to expand and extend their function in response 
to the changing environment in the CNS (Paresce et al. 1996, Koshinaga et al. 
2000, Ramlackhansingh et al. 2011). Proliferation of microglia is fundamental 
for removing cell debris and production of cytokines and other inflammatory 
mediators in the CNS. Activated microglia undergo rapid proliferation that 
involves interactions between cell cycle proteins (Pines 1993, Sherr 1995). 
Cell cycle progression is regulated by complex signaling pathways involving 
several molecules, including cyclins, cyclin-dependent kinases (CDKs), CDK 
inhibitors (CDKIs) and phosphatases (Pines 1993, Sherr 1995). The key 
molecules that control cell cycle are cyclins. Cyclin D forms complexes with 
CDK4 and CDK6 which regulate the G1-S phase transition of the cell cycle 
(Sherr 1995). Moreover, Cyclin D-Cdk4/6 complexes are known to be 
involved in phosphorylation of retinoblastoma protein (pRB), a cell cycle 
inhibitor, during the G1-S phase of the cell cycle progression (Suzuki-
Takahashi et al. 1995, Korenjak & Brehm 2005, Das et al. 2005). pRB 
regulates the activity of E2F1 which is a transcription factor of E2F family, 
involved in cell cycle progression (Suzuki-Takahashi et al. 1995). pRB binds 




E2F) and prevents transcription of S-phase genes. However, phosphorylation 
inactivates pRB and allows E2F-DP to dissociate from pRb and to become 
active (Wu et al. 1995, Korenjak & Brehm 2005).  When E2F is free, it 
activates factors like cyclins and promotes the cells to enter into S phase. 
E2F1-DP1 complex mediates the transactivation of its target genes in the S-
phase.  
CDKIs such as p21 and p27 inhibit a variety of cyclin-CDK complex 
activity resulting in cell cycle arrest at G1/S phase of cell cycle (Toyoshima & 
Hunter 1994). Several signaling molecules including transforming growth 
factor-β (TGF-β) induce p27 expression (Polyak et al. 1994). Very little is 
known about molecular mechanisms that control cell cycle progression of 
microglia except the reports that identified cyclin-D1 mRNA expression in 
microglial cells in the hippocampus of the ischemic rat brain and in microglia 
in glioma (Bosone et al. 2001, Wiessner et al. 1996). An increased number of 
cyclin-D1 and Cdk4-positive microglia was found during neurodegeneration 
induced by kainic acid intoxication (Ino & Chiba 2001). 
Several signaling molecules are known to induce microglial 
proliferation. It has been widely shown that the microglial proliferation in 
vitro as well as in vivo is induced by the colony stimulating factor (CSF), 
including granulocyte macrophage-colony stimulating factor (GM-CSF) 
through the CSF1 receptor (CSF1R) (Kloss et al. 1997, Lodge & Sriram 1996, 
Yamamoto et al. 2010). CSF1R is upregulated in many neurodegenerative 
diseases including AD (Murphy Jr et al. 2000). It has been reported that 
administration of GMCSF increases cyclin-D1 expression and decreases CDK 




factors such as Pleiotrophin (PTN), Neuregulin-1 (NRG-1), interleukin-4 (IL-
4), IL-34, IL-5 and NT3 have also been shown to promote microglial 
proliferation (Elkabes et al. 1996, Miao et al. 2012, Calvo et al. 2010, Mizuno 
et al. 2011). Understating the mechanism of microglial proliferation and its 
contributions to the progression of neurodegenerative diseases (NDs) will 
open up new avenues for potential therapeutic approaches.  
 
1.2.3 Phagocytosis 
Microglia act as macrophages in the CNS, and engulf cellular debris and other 
unwanted materials via phagocytosis. In the brain of AD patients, microglia 
remove Aβ deposits by phagocytosis and thereby prevent the expansion of 
senile plaques (Bard et al. 2000). Microglial phagocytosis of the degenerating 
neurons and apoptotic cells are crucial in reducing neuroinflammation and 
maintaining neuronal survival (Koizumi et al. 2007). These degenerating 
neurons and apoptotic cells release signaling molecules including cytokines 
and chemokines which activate and recruit microglia to the required site. This 
responsiveness of dying neurons or apoptotic cells is known as “find-me, eat-
me and help-me signals”. ‘Find-me’ signals attract and recruit microglia to the 
damaged site, ‘eat-me’ signals help microglia to phagocytose the targets  and 
‘help-me’ signals support  neuronal survival  by inducing microglia to release 
neurotropic factors and anti-inflammatory cytokines (Biber et al. 2007).  
Microglial phagocytosis is classified into two types: phagocytosis 
associated with inflammation and without inflammation (Noda & Suzumura 
2012). They express many surface receptors including purinergic P2X and 




and scavenger receptor, CD36 which are involved in phagocytosis (Koizumi et 
al. 2007, Liu et al. 2005, Stolzing & Grune 2004, Landreth & Reed-Geaghan 
2009). The receptors which are associated with inflammatory response are 
CD14, CD36, TLR1, TLR2, TLR4 and TLR6 (Liu et al. 2005, Stolzing & 
Grune 2004, Landreth & Reed-Geaghan 2009). The receptors that are 
associated with anti-inflammatory response are phosphatidylserine (PS) 
receptors and triggering receptor expressed on myeloid cells-2 (TREM2) 
(Fuller & Van Eldik 2008, Takahashi et al. 2005). Microglia express classical 
phagocytosis-related receptors including complement receptor (CR3), 
CD11b/CD18 and scavenger receptors (CD204) (Reichert & Rotshenker 
2003). CR3 is involved in clearance of bacteria via induction of major 
histocompatibility complex class II (MHCII) during inflammation (Kaur et al. 
2004). CD14 is an LPS receptor that mediates phagocytosis in normal 
condition as well as during inflammation (Lacroix et al. 1998). Aβ in AD 
patients interacts with microglia receptor CD36 (class B scavenger receptor), 
CD47 (integrin associated protein) and RAGE (receptor for advanced 
glycation end products) which are involved in microglial phagocytosis 
(Stolzing & Grune 2004, Koenigsknecht & Landreth 2004, Du Yan et al. 
1996). 
  Microglia express CD200R which is a glycoprotein receptor that leads 
to inhibition of microglial activity when it interacts with its ligand CD200 
(Carter & Dick 2004). Interruption of CD200/CD200R signaling results in 
microglial activation and activated microglial exhibit significant phagocytic 
activity. It has been reported that blocking of CD200R in mouse parkinson’s 




innate immune receptor and its adaptor protein DAP12 are expressed in 
microglia and help in microglial phagocytosis without any inflammatory 
response (Takahashi et al. 2005). PS receptors (PSRs) are also expressed in 
microglia, aiding phagocytosis without inducing inflammation (Fuller & Van 
Eldik 2008). TLRs are expressed in microglia and promote inflammatory 
response and phagocytic ability of microglia (Landreth & Reed-Geaghan 
2009).  
 
1.2.4 Release of cytokine and chemokines by microglia 
Cytokines and chemokines are signaling proteins which bind to specific 
receptors for cell to cell interaction (Borish & Steinke 2003). Microglial cells 
release excessive amounts of cytokines and chemokines when activated by 
various stimuli or in neuropathologies (Hanisch 2002, Dheen et al. 2007). Pro-
inflammatory cytokines are involved in microglial activation and its 
recruitment in neuropathologies (Hanisch 2002). Anti-inflammatory cytokines 
released by microglia help in tissue regeneration and neuronal survival 
(Hanisch 2002). Increased release of pro-inflammatory cytokines and 
chemokines contribute to neuroinflammation and subsequent 
neurodegeneration in the CNS (Dheen et al. 2007). Activated microglia in 
neuropathologies release pro-inflammatory cytokines such as IL-1β, tumor 
necrosis factor alpha (TNF-α), IL-1, IL-6, IL-18 and cyclooxygenase-2 
(COX2) (Nakamura et al. 1999, Rogers et al. 2007). TNF-α binds to its 
receptor, TNFR in microglia and promotes microglia-mediated inflammatory 
response (Hanisch & Kettenmann 2007). TNF-α activates NFκB signaling 




cytokines and promote neurodegeneration (Hanisch & Kettenmann 2007). 
However, activated microglia also produce anti-inflammatory cytokines 
including transforming growth factor β (TGF-β) which reduces 
neuroinflammation. TGF-β reduces microglial proliferation and release of 
neurotoxic factors by activated microglia in response to any pathological 
stimuli in the CNS (Pratt & McPherson 1997).   
Activated microglia produce various chemokines which control the 
influx of inflammatory cells into the CNS (Kremlev et al. 2004). Chemokines 
are divided into three subfamilies, CXC (CXCL10/IP-10), CC (MIP-1α/β, 
MCP-1, RANTES) and CX3C (CX3CL1/fractalkine). Microglial cells express 
chemokines such as monocyte chemotactic protein-1 (MCP-1), macrophage 
inflammatory protein-1α/β (MIP-1α/β), regulated upon activation normal T 
cell expressed and secreted (RANTES) and inducible protein-10 (IP-10) 
(Kremlev et al. 2004) and chemokine receptors CCR3, CCR5, CXCR4 and 
CX3CR1(He et al. 1997, Albright et al. 1999). Chemokines secreted by 
neurons help in the chemotactic migration of microglia to the site of injury or 
infection. TNFα, a pro-inflammatory cytokine has also been shown to induce 
microglial activation and subsequent release of various chemokines (Sheng et 
al. 2005).  
 
1.2.5 Nitric oxide (NO) production by microglia 
Activated microglia produce proinflammtory cytokines and NO excessively in 
neuropathological conditions (Ding et al. 1997). NO is an inter and intra-
cellular messenger that mediates both physiological and pathological effects in 




neurotoxicity (Boje & Arora 1992). The neurotoxicity of NO is primarily due 
to its reactive metabolite peroxynitrite (ONOO
-
), which is formed by its 
reaction with superoxide (Ding et al. 1997, Minghetti & Levi 1998). Nitric 
oxide synthase (NOS) is an  enzyme that catalyses the production of NO from 
L-arginine (Alderton et al. 2001). In mammals, NO production is mediated by 
endothelial NOS (eNOS) and neuronal NOS (nNOS) (Alderton et al. 2001, 
Knowles & Moncada 1994). Inducible NOS (iNOS) is associated with 
immune response and catalyzes the production of NO as a part of its defense 
mechanism (Knowles & Moncada 1994). Ca2
+
-dependent eNOS and nNOS 
catalyze small amounts of NO production whereas Ca2
+
-independent iNOS 
catalyzes large amounts of NO production over a short period of time 
(Knowles & Moncada 1994). Extracellular arginine is required for iNOS-
mediated NO production in activated microglia and peripheral macrophages 
(Closs et al. 2000). Activated microglia show upregulation of iNOS and 
produce excessive amount of NO which contributes to neuronal damage (Boje 
& Arora 1992). 
 
1.2.5.1  Cationic Amino acid Transporter system (CAT) mediated arginine 
transport to CNS 
Among several transport systems, y+ and y+L are the two important transport 
systems that mediate the entry of arginine into the CNS (Closs et al. 2006, 
Nicholson et al. 2001). Y+ system consists of a family of cationic amino acid 
transporters (CAT). Y+ cationic amino acid transporter system is widely 
expressed and considered as an important transporter of arginine in many cell 




transport other cationic amino acids including glutamine. Arginine transport 
via CAT2 transporter is required for the abundant synthesis of NO by 
macrophages (Nicholson et al. 2001).  
 
1.2.5.2 L-aminoacid transporter-2 (LAT2) and its role in NO synthesis 
L-aminoacid transporter-2 (LAT2), a member y+ CAT system has been shown 
to deplete the availability of arginine to nitric oxide synthase (NOS) enzymes 
leading to reduction in NO production (Zielinska et al. 2011, Closs et al. 2006, 
Nicholson et al. 2001). LAT2 induces arginine efflux from the cell in 
exchange of glutamine. Recent study shows that administration of glutamine 
to the extracellular space of the brain reduces NO production via inhibiting 
y+LAT2-mediated arginine uptake and induces arginine efflux from the cell 
(Zielinska et al. 2011). The inhibition of NO synthesis is due to the increased 
y+LAT2 activity which mediates the exchange of intracellular arginine for 
extracellular glutamine. y+LAT2 is responsible for arginine efflux from the 
cells in exchange of the glutamine (Zielinska et al. 2011). This leads to a 
reduction in the availability of intracellular arginine to NOS enzyme for NO 
synthesis.  
 
1.2.6 Role of microglia in synaptic pruning 
Recent studies have identified that microglia play a major role in 
synaptogenesis and pruning/stripping of weaker synapses during normal brain 
development and in neuropathologies (Paolicelli et al. 2011). Synaptic pruning 
by microglia during brain development is essential for synaptic maturation. In 




engulf synaptic materials from the neuronal cell body by a process called 
‘synaptic stripping’ (Moran & Graeber 2004, Tremblay et al. 2010, Paolicelli 
et al. 2011, Trapp et al. 2007). However, in some pathologies including prion 
disease, microglial activation proceeds without synaptic stripping (Perry & 
O'Connor 2010). 
 
1.3 Activation of microglia 
Microglial activation is a hallmark of neuropathologies and chronic activation 
of these cells induces neuroinflammation and subsequent neurodegeneration in 
the CNS. The mechanism of microglia-mediated inflammation has been 
widely studied in vitro, using various stimulants such as Lipopolysaccharide 
(LPS), Aβ, and proinflammatory cytokines which activate microglial cells. 
1.3.1 Lipopolysaccharide (LPS) 
LPS (also known as endotoxin or lipoglycans) is a cell wall component of 
Gram-negative bacteria and elicits a strong immune response in animals (Kulp 
& Kuehn 2010). LPS has been shown to cross blood brain barrier (BBB) 
through diffusion (Cardoso et al. 2010), bind to LPS binding protein (LBP) 
and its receptor CD14, thereby presenting the LPS-LBP complex to Toll-like 
receptor 4 (TLR4) (Chen et al. 2002). The LPS-LBP-CD14 complex interacts 
with TLR4 and triggers an inflammatory signaling cascade including 
activation of MAPKs and NFκB signaling which eventually leads to 
upregulation of proinflammatory cytokines such as TNF-α (Chen et al. 2002, 




several proinflammatory cytokines, NO and reactive oxygen species (ROS) by 
activated microglia (Qin et al. 2005, Huo et al. 2011, Jung et al. 2007). 
1.3.2 β- amyloid protein (Aβ) 
The brains of AD patients show abundant neurofibrillary tangles and 
aggregates of insoluble Aβ that are accompanied by microglial activation 
(Meda et al. 1995). Aβ has been shown to trigger microglial activation and 
production of TNF-α and reactive nitrogen intermediates (Meda et al. 1995, 
Barger & Harmon 1997). Microglia when exposed to Aβ exhibit chemotactic, 
phagocytic and secretary activity (Rogers & Lue 2001). Microglial activation 
upon Aβ treatment in vitro causes neurotoxicity (Meda et al. 1995).  Aβ 
attracts and activates microglia to produce inflammatory mediators, some of 
which further induce microglia activation and tissue damage (Rogers & Lue 
2001). 
 
1.4 Animal models for studying microglial activation and 
function 
1.4.1 Activation of microglia in various neurodegenerative diseases 
 Chronically activated microglia play a major role in both vascular and 
neuronal damage in various pathological conditions and neurodegenerative 
disorders such as Alzhiemer’s disease (AD), Parkinson’s disease (PD) and 
Multiple sclerosis (MS) (Qin et al. 2002, McGeer et al. 1988, Benveniste 




1.4.1.1 Microglial activation in Alzheimer’s disease (AD) 
AD is one of the neurodegenerative disorders associated with the toxic effect 
of microglia activation (Qin et al. 2002). Deposition of Aβ plaques and 
neurofibrillary tangles within the brain accompany microglial activation which 
causes neuronal damage in patients with AD (Qin et al. 2002, Combs et al. 
2000, Rogers & Lue 2001). Activated microglia cluster around the deposition 
of Aβ which is proinflammatory and activates the microglia cluster to release 
neurotoxic factors such as TNF-α, NO and ROS (Qin et al. 2002, Combs et al. 
2000, Sasaki et al. 1997, Rogers & Lue 2001).  Chronic microglial activation 
in AD patients leads to memory impairment and cognitive decline (Xiang et 
al. 2006). 
 
1.4.1.2 Microglial activation in various other neurological disorders 
Parkinson’s disease (PD) is caused by the death of dopaminergic (DA) 
neurons in the substantia nigra region of the mid brain, resulting in motor 
dysfunctions (Langston et al. 1999).  Activated microglial cells were found to 
be distributed in the vicinity of dying neurons in the substantia nigra, 
hippocampus and cingulate cortex of patients with PD (McGeer et al. 1988, 
Zhang et al. 2005). DA neurons secrete several factors such as neuromelanin 
and MMP3 (a proteinase that degrades extracellular matrix) that activate 
microglia which augment neuroinflammation in the brain (Kim et al. 2007b). 
In addition, microglia have been linked to the pathology and disease 
progression in various other neurodegenerative disorders including, multiple 
Sclerosis (MS), Huntington’s disease, HIV-associated dementia, and Pick’s 




1993, Raghavendra Rao et al. 2000). All these reports suggest that microglial 
activation is a characteristic feature of neurological disorders. 
 
1.4.1.3  Microglial activation in stroke 
Microglial activation is one of the early responses to stroke caused by 
ischemia or hemorrhage. Microglial response to ischemic stroke includes its 
rapid proliferation, migration, and the production of NO, ROS, superoxide, 
proinflammatory cytokines and proteases that exacerbate acute ischemic injury 
(Yenari et al. 2010, Lakhan et al. 2009, Lucas et al. 2006). Microglial 
response to brain ischemia can be classified into three phases: a sensory phase 
involving detection of extracellular signals using its surface and intracellular 
receptors, a signal transduction component which influences the gene 
expression based on these signals and an effector component which activates 
many inflammatory responses (Yenari et al. 2010). 
 
1.4.1.4 Microglial activation in brain tumor  
1.4.1.4.1 Glioma 
Microscopic analysis of high grade glioma revealed that microglial cells are 
activated in glioma and form a dense band around the tumor mass (Wei et al. 
2013). It has been reported that microglial infiltration in gliomas is facilitated 
by several chemokines, cytokines and growth factors  including monocyte 
chemotactic protein-3 (MCP-3), TNFα, hepatocyte growth factor (HGF), 
Granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage 
colony stimulating factor (M-CSF) and glial-derived neurotrophic factors 




2005, Pyonteck et al. 2013). Though microglial response to brain tumors is 
evident, it is unclear whether this activation is a part of its anti-tumor defense 
mechanism or a tumor supportive mechanism. 
 
1.4.1.5 Activation of microglia in developmental disorders 
1.4.1.5.1 Autism 
Activated microglial cells were found in multiple brain regions of patients 
with autism which is a neurodevelopmental disorder (Zeidán-Chuliá et al. 
2014). Increased production of TNFα, IL-6 and MCP-1 were observed in the 
brains of patients with autism spectrum disorder (ASD) (Suzuki et al. 2013). 
Microglial activation was quantitatively assessed in the dorsolateral prefrontal 
cortex of postmortem brains of young and adults with ASD (Suzuki et al. 
2013). Various environmental as well as genetic factors are involved in the 
progression of autism disorder during pregnancy. The environmental factors 
related to autism disorders are cadmium, ethanol, mercury, and nickel which 
are known to activate microglia that produce proinflammatory cytokines and 
ROS (Zeidán-Chuliá et al. 2014). Environmental factors may also contribute 
to epigenetic changes including disruption of micro RNAs (miRNA) which 
could lead to oxidative stress and neurotoxicity in patients with autism 
disorder (Zeidán-Chuliá et al. 2014).  
 
1.4.1.6 Microglial activation in brain injury 
1.4.1.6.1 Traumatic Brain Injury (TBI) 
Traumatic brain injury (TBI) causes irreversible damage resulting in 




classified into two phases: the initial primary phase and an ongoing secondary 
phase (Kumar & Loane 2012). The initial primary phase is the injury itself and 
the secondary phase starts from the time of injury and continues for several 
months (Kumar & Loane 2012). Primary phase leads to acute 
neuroinflammation in the brain and the secondary phase leads to chronic 
inflammation (Ramlackhansingh et al. 2011). One of the vital inflammatory 
responses to brain injury is activation of microglia (Koshinaga et al. 2000, 
Faden 2011). Brain injury activates microglial cells, which in turn causes the 
release both pro- and anti-inflammatory factors that modulate the secondary 
phase of the injury and recovery post-injury (Loane & Byrnes 2010). 
Activation of microglial cells upon brain injury triggers the release of pro-
inflammatory cytokines, chemokines, ROS and NO which augment 
neuroinflammation and subsequent neurodegeneration in the CNS (Faden 
2011). Upon brain injury, the resting microglia in the adult brain contract their 
processes to attain an amoeboid shape, followed by proliferation and 
migration towards the injury site (Vilhardt 2005). This convergence of 
activated microglia is in response to the factors released by the injured neurons 
(Davalos et al. 2005). Microglia express receptors for factors including ATP, 
cytokines, glutamate and growth factors which are released by injured neurons 





1.5 Regulatory pathways/genes mediating microglial 
activation  
Molecular mechanisms by which microglia are activated and mediate 
neuroinflammation have been widely studied in vitro and in vivo. Several 
regulatory genes and pathways have been shown to control microglia 
activation and microglia-mediated neuroinflammation (Dheen et al. 2002). 
Developing therapeutic drugs to target these potential candidates would help 
to attenuate microglia-mediated neuroinflammation in various 
neurodegenerative disorders. Some of the major regulatory genes and 
pathways have been discussed in detail in the following section. 
 
1.5.1 Mitogen-activated protein kinase pathway (MAPK) 
MAP kinase pathway (MAPK) is one of the important signaling pathways 
responsible for inducing inflammatory gene expression (Deng et al. 2008, 
Kaminska 2005). Several reports have demonstrated that microglial response 
to extracellular stimuli is mediated by the MAPK pathway (Deng et al. 2008). 
It plays a major role in controlling microglial activation and production of 
neurotoxic factors in various neurodegenerative disorders including AD and 
stroke (Zhu et al. 2003, Sawe et al. 2008). MAPK family members include 
three subgroups:  the JNK/stress- activated protein kinase, p38 MAP kinase 
and extracellular signal-regulated kinase (ERK) (Sawe et al. 2008, Hommes et 
al. 2003). These three MAPKs are phosphorylated by specific upstream 
MAPK kinases at the tyrosine and threonine residues (Park et al. 2002). 




subsequent downstream targets including protein kinases and nuclear 
transcription factors resulting in transcription of corresponding MAPK 
regulated genes (Deng et al. 2008).  
MAPK pathways can be deactivated by dephosphorylation by MAPK 
phosphatases such as MAPK phosphatase-1 (MKP1). MKP1 functions as an 
important negative feedback regulator of microglial function and 
inflammatory response by inhibiting the p38 MAPK pathway and its 
downstream gene such as TNF-α (Clark 2003). 
Nuclear factor-κB (NFκB) is one of the downstream targets of MAPK 
pathways and is involved in the neuroinflammation (Smoak & Cidlowski 
2004). NFκB is a ubiquitous transcription factor consisting of homodimers or 
heterodimers assembled from various subunits including p65 (Rel A), c-Rel, 
Rel B, p50/p105 and p52/p100 (Brasier 2006, Nakamichi et al. 2007). NFκB 
activation is controlled by its associated protein I-κB. In the presence of I-κB, 
NFκB is present in the cytoplasm of microglial cells (Nakamichi et al. 2007, 
Quan et al. 2000). Upon microglial activation, NFκB is activated and 
translocated into the nucleus of the cell via an I-κB kinase (IKK)-dependent 
phosphorylation of I-κB, followed by its ubiquitination and degradation (Quan 
et al. 2000). The NFκB protein which is translocated to the nucleus 
transactivates many of its downstream target genes including TNFα, IL-1β, 
and iNOS (Brasier 2006). 
 
1.5.2 NADPH Oxidase 2 (Nox2 /gp91phox) 
Nox2 (or gp91phox) is one of the important regulatory genes expressed in 




NADPH oxidases and is involved in regulating reactive oxygen species (ROS) 
production in activated microglia. NOX-mediated ROS production and nitric 
oxide (NO) release in microglia have been implicated in various 
neurodegenerative disorders (Dohi et al. 2010). NOX2 expression was 
upregulated in activated microglia following TBI and promoted ROS 
formation resulting in neurodegeneration (Dohi et al. 2010). Thus, modulating 
Nox2-mediated ROS production may help in providing better therapeutic 
treatments for patients suffering from TBI (Dohi et al. 2010). It has been 
shown that dexamathasone, a synthetic glucocorticoid, inhibits microglial 
activation by downregulating Nox2 (Huo et al. 2011, Dohi et al. 2010) via 
inhibiting p38/JNK MAPK pathways (Zhou et al. 2007, Huo et al. 2011). 
These findings suggest that Nox2 is an important regulatory factor in 
controlling microglia-mediated neuroinflammation. 
 
1.5.3 Notch family 
Microglial cells have been shown to express Notch-1 receptor (Cao et al. 
2008). Notch-1 is a transmembrane receptor which mediates the release of 
inflammatory mediators (Cao et al. 2011, Mumm et al. 2000). In AMC, Notch 
receptor is found co-localized with its ligands, Jagged-1 and Delta-1 (Cao et 
al. 2008). It has been reported that Notch-1 is involved in regulating the 
expression of proinflammatory cytokines and iNOS by modulating the NF-
κB/p65 pathway in activated microglia (Cao et al. 2011). N-[N-(3,5-
difluorophenacetyl)-1-alany1]-S-phenylglycine t-butyl ester (DAPT), an 




proinflammatory cytokines production in activated microglia (Cao et al. 
2011). 
 
1.5.4 Sphingosine kinase 1 (SphK1) 
Recently, our group has reported that sphingosine kinase 1 (SphK1), a key 
enzyme responsible for sphingolipid metabolism, and its receptors are 
expressed in microglia (Nayak et al. 2010, Lin et al. 2011). SphK1 expression 
was induced in activated microglial cells both in vitro and in vivo (Nayak et al. 
2010, Lin et al. 2011). Further, this induction was found to increase the 
production of proinflammatory cytokines and NO (Nayak et al. 2010, Lin et 
al. 2011). An inhibitor of SphK1 named N, N Dimethylsphingosine (DMS), 
suppressed SphK1 induction, proinflammatory cytokine production and 
release of NO in activated microglial cells by inhibiting NFκB signaling 
pathway (Nayak et al. 2010, Lin et al. 2011). In view of the above findings, 
SphK1 appears to be one of the potential targets for the treatment of 
microglia- mediated neuroinflammation. 
 
1.5.5 Peroxisome Proliferator Activated Receptor Gamma (PPARγ) 
PPARs are ligand activated transcription factors belonging to the family of 
nuclear receptors which control its target gene expression in response to 
binding with ligands (Duez et al. 2001, Braissant et al. 1996). Once activated 
by ligands, PPARs form complexes with retinoid X receptor (RXR) and bind 
to the PPAR response element (PPRE) located at the  promoter region of its 
targets (Chinetti et al. 2000). There are three types of PPAR isoforms, PPARα, 




microglia with pleoitropic effects on lipid and glucose homeostasis and control 
of inflammation (Kapadia et al. 2008, Schintu et al. 2009). Activation of 
PPARγ reduces neuroinflammation in the brain (Kersten et al. 2000, 
Sundararajan et al. 2006) by inhibiting NFκB signaling pathway (Vandoros et 
al. 2006). PPARγ shows basal level of transcriptional activity without ligand 
binding, but its activity increases when stimulated by ligands (Braissant et al. 
1996). PPARγ ligands such as rosiglitazone, piogliatazone, trogliatazone and 
cigitazone exhibit anti-inflammatory effects by binding to PPARγ in glial cells 
(Gonon et al. 2007, Youssef & Badr 2013, Belvisi et al. 2006, Pan & Chen 
2003). They repress the expression of several inflammatory response genes 
including TNF-α, IL-6, IL-1β and iNOS (Burston & Kendall 2013, Pan & 
Chen 2003, Gonon et al. 2007). PPARγ agonists have been shown to exert 
neuroprotection following cerebral ischemia, AD and PD (Collino et al. 2008, 
Chaturvedi & Beal 2008). Activation of PPARγ by ligands reduces the 
production of ROS and NO in stroke, indicating the neuroprotective role of 
PPARγ agonists which can be used as effective drugs for treating stroke and 
other neurological disorders (Sundararajan et al. 2006, Collino et al. 2008).  
 
1.5.6 Epigenetic factors  
Recent studies demonstrated that epigenetic factors including histone 
modifications, DNA methylation and non-coding RNAs such as microRNAs 
are involved in modulating the immune response of microglia  (Garden 2013). 
It has been shown that DNA methylation in microglia influences the 
expression pattern of several genes associated with AD (Byun et al. 2012, Lin 




expression in microglia (Halili et al. 2009). Histone deacetylase inhibitors 
(HDACi) such as valproic acid and sodium butyrate have been shown to have 
anti-inflammatory effects and suppress the microglia-mediated 
neuroinflammation by preventing the transcription of proinflammatory genes 
(Xuan et al. 2012). It has been widely suggested that HDACi can be used as 
potential therapeutic drugs in treating microglia-mediated neuroinflammation 
due to their anti-inflammatory and neuroprotective effects (Halili et al. 2009, 
Shakespear et al. 2011).  
 MicroRNAs (miRNAs) are the prominent form of non-coding RNAs 
which control gene expression at transcriptional and post-transcriptional level 
(Chen & Rajewsky 2007). They are short single stranded RNA molecules with 
22 nucleotides in length. miRNAs bind to the 3’untranslated region (3’UTR) 
of the target mRNAs and suppress their expression either by promoting 
degradation or by preventing translation (Lim et al. 2005). miRNAs such as 
miR-155, mir-146a, miR-124 have been shown to play important roles in 
modulating inflammatory response of microglia (Cardoso et al. 2012, Li et al. 
2011, Ponomarev et al. 2010).  Recent study from our lab demonstrated that 
microglia express miR-200b which modulates the immune response of 
microglia by targeting the cJun MAPK-pathway (Jadhav et al. 2014). 
 
1.5.7 Runt-related transcription factors (Runx) family  
RUNX family members are transcription factors involved in regulating the 
G0/G1 and G1-S phase transition of cell cycle and differentiation (Wang et al. 
2010, Durst & Hiebert 2004, Strom et al. 2000). They are mainly required for 




repression involves recruitment of corepressors such as histone deacetylases 
(HDACs) (Durst & Hiebert 2004). RUNX family consists of three members, 
Runx1, Runx2 and Runx3 (Durst & Hiebert 2004). Overexpression of Runx1 
in hematopoietic cells showed a shortened G1 phase and a rapid S phase entry 
of cell cycle indicating that Runx1 is a positive regulator of G1-S phase 
transition (Strom et al. 2000). Runx2 is involved in bone formation 
particularly during the proliferation and differentiation of osteoblasts (Otto et 
al. 1997). Runx3 is required for the development of nervous system (Inoue et 
al. 2002). Runx3
-/- 
mice showed defect in the development of T cells and 
dorsal root ganglion neurons (Inoue et al. 2002, Levanon et al. 2002). Runx2 
and Runx3 also act as the accelerator of cell proliferation (Bernardin-Fried et 
al. 2004). 
Runx1 has been shown to be expressed in AMC of the postnatal mouse 
brain and its expression is downregulated in RMC but induced in activated 
microglial cells post-TBI (Logan et al. 2013, Zusso et al. 2012). It has been 
shown that Runx1 inhibits proliferation of mouse AMC and promotes 
progression to the ramified state (Zusso et al. 2012). Recent studies 
demonstrated that RUNX1+ yolk sac progenitors seed the brain through blood 
circulation between embryonic day 8.5 and 9.5 and these cells differentiate to 
form microglia during development (Ginhoux et al. 2010). All these findings 
indicate that the RUNX family plays a pivotal role in the proliferation and 





1.5.7.1 Runt-related transcription factor 1; translocated to, 1(Runx1t1) 
Runx1t1 (also known as CDR, ETO, MTG8), a member of RUNX family has 
been shown to be involved in the proliferation and differentiation of 
hematopoietic stem cells (Okumura et al. 2007, Davis et al. 2003). Runx1t1 
protein is composed of a series of evolutionarily conserved domains which 
contains four nervy homology regions (NHR, Fig. I). Runx1t1 has been shown 
to be expressed in several human tissues, with its highest expression in the 
brain and heart (Zhang et al. 2001, Zhang et al. 2009). Its expression has been 
localized in the nucleus and cytoplasm of neural cells (Sacchi et al. 1998). 
Runx1t1 acts as a transcriptional repressor by recruiting a nuclear co-repressor 
complex containing HDACs (Gelmetti et al. 1998, Lutterbach et al. 1998, 
Davis et al. 2003, Wang et al. 1998), which regulate cell cycle progression by 
repressing Cdk inhibitors, p21 and p27 through histone deacetylation (Mathew 
et al. 2010) (Fig. II). This repression upregulates the expression of cell cycle 
genes, Cdk4 and Cdk6 (Mathew et al. 2010, Baumann et al. 2012) (Fig. II). In 
myeloid cells, Runx1t1 has been shown to recruit class 1 HDACs for 
transcriptional repression (Oakford et al. 2010). Microarray study from our lab 
showed that Runx1t1 was highly expressed in amoeboid microglial cells in the 
postnatal rat brain when compared to the ramified microglia of the adult brain 
(Parakalan et al. 2012). This suggested that Runx1t1 may be involved in 







Fig. I: Illustration showing the evolutionarily conserved domains of Runx1t1 
and the regions involved in binding to Runx1t1-interacting proteins such as 
nuclear co-repressor (N-CoR), silencing mediator of retinoic acid and thyroid 
hormone receptors (SMRT) and histone deacetylases (HDACs) [Adapted and 
modified from (Davis et al. 2003)] 
 
1.5.7.2 Histone deacetylases (HDACs) mediate cell proliferation and 
transcriptional repression 
Histones are the primary protein component of chromatin and compact the 
DNA (Kornberg 1974). Chromatin modifying enzymes alter histone proteins 
by adding or removing some molecules (Yang & Seto 2007). These 
modifications alter chromatin structure and influence gene transcription. For 
example, histones of the nucleosomal core are acetylated by histone acetyl 
transferase (HATs) enzymes and the acetylation can be deacetylated by 
histone deacetylase (HDACs) enzymes (Yang & Seto 2007). HDACs remove 
acetyl group from the lysine residues located at the histone tail which restores 
a positive charge to the lysine leading to nucleosome condensation and 
transcriptional repression (Peserico & Simone 2010) (see Fig. II). HDACs are 










HDACs and class IV HDACs (De Ruijter et al. 2003). Many leukemogenic 
transcription factors recruit HDACs to repress the expression of their target 
genes (Yoshida et al. 2001). It has been reported that in acute myeloid 
leukemia, the fusion protein Runx1-Runx1t1 recruits HDACs for transcription 
repression (Paschka 2008, Mrózek et al. 2008).  
HDACs which catalyze histone deacetylation and chromatin 
condensation, are involved in controlling cell proliferation by regulating the 
cell cycle genes (Baumann et al. 2012, Mathew et al. 2010, Kouzarides 1999, 
Faraco et al. 2009). HDAC-mediated chromatin remodeling upregulates the 
expression of Cdk4 which forms complex with cyclin D1 and phosphorylates 
retinoblastoma protein (pRb) which in turn regulates the G1/S transition in the 
cell cycle (Ferreira et al. 2001, Mathew et al. 2010, Korenjak & Brehm 2005, 
Luo et al. 1998, Das et al. 2005). HDAC inhibitor (HDACi) has been shown 
to induce deregulation of cell cycle genes, cyclin D1 and Cdk4 leading to 
hypophosphorylation of pRb (Baumann et al. 2012), thereby resulting in cell 
cycle arrest in multiple myeloma cells. Further, in the adult neural stem cells, 
HDACi treatment induced the transcriptional activity of Cdk inhibitors, such 
as p21 and p27 together with histone acetylation at proximal promoter regions, 






Fig. II: Illustration showing the Runx1t1-mediated recruitment of HDACs to 
the promoter region of its target gene. Runx1t1 binds to target gene promoter 
and recruits HDACs to deacetylate histones near the promoter region, thus 
inducing transcriptional repression. [Adapted and modified from (Minucci & 
Pelicci 2006)] 
 
1.5.7.3  HDAC inhibitors in controlling microglial proliferation and 
microglia-mediated neuroinflammation. 
HDAC inhibitors (HDACi)  such as valproic acid, sodium butyrate, and 
suberoylanilide hydroxamic acid (SAHA) have been shown to inhibit 
microglial activation, resulting in reduction of neuroinflammation and 
neurodegeneration in the CNS (Suuronen et al. 2003, Huuskonen et al. 2004). 
HDACi derepress or reverse transcriptional repression by blocking HDAC 
activity (Kazantsev & Thompson 2008). Initially, HDACi were used as the 




nervous system disorders (Kazantsev & Thompson 2008). In TBI and 
ischemic model, HDACi exert neuroprotective effects by stimulating 
neurogenesis and neuronal differentiation, and restoring learning and memory 
(Kim et al. 2009, Fischer et al. 2007, Vecsey et al. 2007). HDACi such as 
SAHA and sodium butyrate exert anti-proliferative effect in vitro in adult 
mouse neural stem cells (NSCs) by blocking the G1/S phase transition of the 
cell cycle (Kouzarides 1999, Zhou et al. 2011). Blocking of G1 phase by 
HDACi upregulates the expression of Cdk inhibitors such as p21 and p27 and 
downregulates Cdk2 and Cdk4 expression in NSCs (Zhou et al. 2011).  
Trichostatin A (TSA), a HDAC inhibitor, induces cell cycle arrest at both G1 
and G2 phase of cell cycle (Kouzarides 1999) and reduces the LPS-induced 
expression of proinflammatory cytokines, iNOS and NO production in 
microglia by inhibiting NFκB signaling pathway (Suuronen et al. 2003). 
SAHA also inhibits the LPS-induced inflammatory response of primary 
microglial cells (Suuronen et al. 2003). Valproic acid induces microglial 
apoptosis and reduces LPS-induced neurotoxicity (Chen et al. 2007). HDACi 
exhibit neuroprotecive and anti-inflammatory effects in rat ischemic model of 
stroke (Kim et al. 2007a). Further, HDACi have been shown to reduce 
microglial inflammatory response in TBI and other neurological disorders by 
inducing acetylation (Zhang et al. 2008). Therefore, it has been suggested that 
HDACi such as SAHA, TSA and sodium butyrate could be considered as 





1.6 Therapeutic strategies to treat microglia-mediated 
neuroinflammation 
Targeting regulatory genes and pathways that suppress inflammatory response 
of microglia in the CNS is a viable therapeutic approach for the treatment of 
neurodegenerative disorders. Drugs with anti-inflammatory properties possess 
inhibitory effects on the activation and subsequent inflammatory response of 
microglia. For example, glucocorticoids, minocycline, melatonin, retinoic 
acids, and HDACi such as valproic acid, SAHA and sodium butyrate have 
been shown to inhibit microglial activation, thereby reducing 
neuroinflammation and neurodegeneration in the CNS (Huo et al. 2011, Tikka 
et al. 2001, Kaur et al. 2008, Chung & Han 2003, Dheen et al. 2005, 
Shakespear et al. 2011, Huuskonen et al. 2004, Suuronen et al. 2003). 
However, these drugs do not appear to be specific to microglia and chronic use 
of these drugs is often associated with harmful side effects. 
Many herbal compounds with limited side effects have been used in 
treating microglia-mediated neuroinflammation. Herbal compounds such as 
resveratrol, curcumin, ginsenoside, parthenolide (PTN) and costunolide have 
been shown to have a potential inhibitory effect on microglial activation and 
subsequent neuroinflammation in the CNS (Rayan et al. 2011, Rangarajan et 
al. 2013, Park et al. 2009, Magni et al. 2012, Dheen et al. 2007). Most of these 





1.6.1 Costunolide for treating microglia-mediated neuroinflammation  
Costunolide (Cos), a herbal compound isolated from the root of Saussurea 
lappa Clarke, is a medicinal herb known to have anti-inflammatory properties 
(Pandey et al. 2007, Rayan et al. 2011, Kang et al. 2004). Many 
pharmacological experiments demonstrated the ability of Saussurea costus to 
exhibit anti-inflammatory properties in a number of in vitro and in vivo 
models. Costunolide has been shown to inhibit NFκB transcription activity, 
NO production, and IL-1β expression by suppressing the activation of MAPK 
pathway  in LPS activated macrophages (Kang et al. 2004). We have shown 
that costunolide suppresses the microglial activation by inhibiting the NFκB 
signaling pathway in vitro (Rayan et al. 2011). However, the mechanism of 
action of costunolide on microglial activation is still unknown.  It appears that 
costunolide exerts the anti-inflammatory effect by binding to a specific 
receptor in the microglia.  
1.6.1.1 In slilico analysis predicts that costunolide has strong binding 
affinity for PPARγ receptor 
In silico docking method was used to predict the receptor or protein to which 
costunolide binds and brings about attenuation of microglial activation. 
Interaction of costunolide was analyzed with a few microglial receptors 
including Peroxisome proliferator-activated receptor gamma (PPARγ). 
PPARγ, a ligand-activated transcription factor functions as a transcriptional 
modulator which inhibits transcription of proinflammatory mediators. In silico 
docking prediction shows that costunolide is a ligand of good affinity for 




reporter assay also showed that costunolide binds and activates PPARγ 
receptor in microglia (data not shown). 
 
 
Fig. III. Docking of costunolide inside PPARγ receptor. Molecular docking 
analysis predicts strong affinity binding of costunolide (ball shape structure, 
red; arrows) with PPARγ receptor (ribbon shape structure, blue; arrows) 
[Adapted from Rayan, N.A, PhD thesis, 2011] 
 
 
1.6.2 Suitability of murine BV2 microglial cell line as an appropriate 
alternative system for primary microglia and animal models. 
BV2 microglial cells which are immortalized neonatal mouse microglial cell 
line (Bocchini et al. 1992), are used as an appropriate alternative model 
system for primary microglial cells and animal model for studying microglia-
mediated neuroinflammation (Henn et al. 2009). The response of BV2 
microglial cells to LPS is similar to the response of primary microglial cells in 












primary microglia showed a similar inflammatory gene expression profile 
upon activation with LPS (Henn et al. 2009). BV2 microglial cells also 
express receptors required for microglia-neuron interaction and also release 
factors which allow them to interact with other glial cells (Bocchini et al. 
1992). Thus, BV2 microglial cells appear to be an appropriate substitute for 
primary microglial cells in many experimental set ups including siRNA 
transfection, overexpression and other functional assays. 
 
 
1.7 Scope of the study 
In various pathological conditions, microglia undergo rapid proliferation and 
release a plethora of proinflammatory cytokines and neurotoxic molecules, 
which help in removing damaged or infected neurons. On the other hand, 
chronic activation of microglia leads to excessive release of proinflammatory 
cytokines and neurotoxic molecules, which appear to exacerbate the 
neuroinflammation and subsequent neurodegeneration. Microglial activation 
seems to be influenced by various signaling molecules and transcription 
factors (TFs) (Dheen et al. 2002). Analyzing the function of these signaling 
molecules/TFs in microglial activation and developing potential drugs to 
target these molecules/TFs could possibly help attenuating microglia-mediated 
neuroinflammation in neurodegenerative disorders. Studies show that 
regulatory factors such as MAPK, NFκB, NOX2, SphK1 and several 
epigenetic factors control the chronic activation and inflammatory response of 




drugs and herbal extracts have been shown to suppress microglial activation 
by targeting these factors (Rangarajan et al. 2013).  
The present study was aimed at understanding: (a) the expression 
pattern and role of Runx1t1, a transcription factor, in microglia and (b) 
elucidating the therapeutic potential and mechanism of action of costunolide, a 
herbal compound on the inflammatory response of activated microglia  
Runx family members (a family of transcription factors) have been 
shown to play an important role in the development and activation of 
microglia (Logan et al. 2013, Zusso et al. 2012). Moreover, recent studies 
identified  that microglial cells are originated from Runx1 positive cells in the 
yolk sac (Ginhoux et al. 2010). Recent microarray analysis to show the 
differential gene expression of AMC and RMC by our group revealed that 
Runx1t1, another member of Runx family known to control cell proliferation, 
was expressed exclusively in AMC, but not in RMC (Parakalan et al. 2012). 
Hence, determining the temporal expression and function of Runx1t1 in 
microglia could be vital in understanding the molecular mechanism behind the 
development and activation of microglia. Therefore, it was hypothesized 
that Runx1t1 is expressed in the amoeboid microglia and regulates the 
proliferation, morphological transformation and possibly, activation of 
microglia. In view of this, the expression pattern and functional analysis of 
Runx1t1 in microglia were carried out in this study. Runx1t1 expression was 
studied in normal and activated microglial cells of inflammation model, brain 
injury rat model and AD rat model. In vitro analysis using BV2 microglial cell 
line was performed to study the functional role of Runx1t1 in activated 




function of Runx1t1 in activated microglia.  BV2 microglia were treated with 
HDACi to study the interaction between Runx1t1 and HDACs in controlling 
microglial activation.  
    Microglial cells are chronically activated in brain injury models and 
mediate neuroinflammation by releasing inflammatory cytokines, chemokines, 
ROS and NO (Streit 2000, Davalos et al. 2005, Dheen et al. 2007) Various 
anti-inflammatory drugs and herbal compounds have been identified in 
treating microglia mediated neuroinflammation in brain injuries (Zhang et al. 
2008, Mejia et al. 2001). Herbal compounds with limited side effects in 
treating microglia-mediated neuroinflammation would open up new avenues 
in neurodegenerative disease therapy. Therefore, understanding the 
mechanism of action of these herbal compounds is essential in treating 
neuroinflammation. Costunolide (Cos), an anti-inflammatory herbal 
compound has been shown to have an inhibitory effect on microglial 
activation (Rayan et al. 2011). Recent in silico docking studies from our group 
showed that costunolide has a strong binding affinity with PPARγ receptor. 
Considering the fact that PPARγ receptor is expressed in microglial cells, it is 
hypothesized that costunolide delivers its anti-inflammatory effects by 
binding and activating PPARγ receptor, an inhibitor of NFκB signaling 
pathway. In the present study, we examined the effect of costunolide in 
controlling microglial activation in the rat brain post-TBI and tested the 
hypothesis that costunolide reduces microglia mediated neuroinflammation by 
modulating the NFкB/ PPARγ pathway. PPARγ loss of function analysis 
using dominant negative (DN) PPARγ was carried out in BV2 microglial cells 




costunolide on microglial activation is via PPARγ receptor. These findings 
would offer better understanding of the potential candidates that control 
microglial activation and also provide new therapeutic strategies in treating 
microglia-mediated neuroinflammation post-TBI. 
      
1.8 Specific aims of the study 
The first part of the study mainly focused on analyzing the function of 
Runx1t1 which appears to control microglial activation and microglia-
mediated neuroinflammation. 
1.8.1 To investigate the expression pattern of Runt related transcription 
factor 1, translocated to, 1 (Runx1t1) in microglia both in vivo and 
in vitro 
Recent microarray study showed that Runx1t1, a transcription factor that 
belongs to Runx family, was highly expressed in the AMC isolated from the 
corpus callosum (CC) of post-natal rat brain (Parakalan et al. 2012). To 
examine the expression pattern of Runx1t1 in microglia both in vitro and in 
vivo: 
a) The temporal expression pattern of Runx1t1 was studied in AMC in 
the corpus callosum of early postnatal rat brain and RMC in the corpus 
callosum of the adult brain.  
b) Expression of Runx1t1 was studied in both control and LPS-activated 





1.8.1.1 To understand the expression levels of Runx1t1 in activated 
microglia in vivo 
a)  The expression levels of Runx1t1 were examined in activated 
microglial cells in the inflammation model, TBI rat models and AD rat 
models.  
 
1.8.1.2 To understand the role of Runx1t1 in activated microglia 
Since Runx1t1 has been shown to be involved in proliferation and microglial 
proliferation is the hallmark of brain injury and neurodegenerative diseases, it 
was hypothesized that Runx1t1 that has been shown to be expressed in AMC 
is involved in microglial proliferation and activation. 
To address the functions of Runx1t1 in microglia: 
a)  The effect of siRNA-mediated knockdown of Runx1t1 on the 
proliferation index of BV2 microglia was studied. 
b) The effect of siRNA-mediated knockdown of Runx1t1 on the 
expression level of Cdk4, a cell cycle gene was studied in BV2 
microglial cells. 
 
1.8.1.3 To investigate the association between Runx1t1 and HDACs in 
controlling microglial proliferation and activation 
Since, Runx1t1 acts as a transcriptional repressor by recruiting HDACs 
(Gelmetti et al. 1998, Lutterbach et al. 1998, Davis et al. 2003, Wang et al. 
1998), and regulates cell cycle progression by upregulating the cell cycle 




Baumann et al. 2012),  it was hypothesized that Runx1t1 is associated with 
HDACs in controlling microglial proliferation. To examine this:  
a) Sodium butyrate, one of the HDACi was used to mimic the effects of 
Runx1t1 knockdown on BV2 microglia. 
b) Effects of HDACi treatment on the proliferation index of BV2 
microglia were studied. 
 
1.8.1.4 To determine if the repression of LAT2 by Runx1t1 is HDAC 
mediated in activated microglia. 
As it has been reported that Runx1t1 recruits HDACs for transcription 
repression of its target genes, it was hypothesized that Runx1t1 recruits 
HDACs to transcriptionally repress its target gene, LAT2 in microglia. To 
address this: 
a) Effects of Runx1t1 knockdown and HDACi treatment on theLAT2 
expression in BV2 microglia were studied. 
b) ChIP assay was carried out to study the interaction between Runx1t1 
protein and LAT2 gene promoter. 
 
1.8.2 To elucidate the therapeutic potential of costunolide, a herbal 
compound, for the treatment of microglia-mediated 
neurotoxicity after TBI. 
The chronic activation of microglia is often associated with excessive 
production of inflammatory mediators and cytotoxic molecules. 
    Several drugs with neuroprotective and anti-inflammatory properties 




using these drugs are their side effects. Identifying potential herbal compounds 
which possess neuroprotective and anti-inflammatory properties have 
promising role in treating microglia-mediated neuroinflammation and 
neurodegeneration due to its limited side effects. In this connection, we 
proposed to investigate the mechanism of action and therapeutic potential of 
costunolide, a herbal compound on the inflammatory response of microglia 
post-TBI.  
    We have previously shown that costunolide suppresses microglial 
activation by inhibiting the NFκB signaling pathway in LPS-activated BV2 
microglia (Rayan et al. 2011). Hence, it was hypothesized that costunolide, 
suppresses the inflammatory response and the neurotoxic effects of microglial 
cells and may aid in the development of better therapeutic strategies for 
treating patients with neuroinflammation post-TBI.  
To address this:  
a) Effects of costunolide on the inflammatory response of microglia were 
studied in the rat brain post-TBI. 
b) Effects of costunolide on the expression of several signaling pathways 
and regulatory molecules such as MKP1, SphK1, Runx1t1, NFκB and 
TNFα were studied in the activated microglia in the rat brain post-TBI. 
 
1.8.2.1 To elucidate the mechanism of action of costunolide on the 
inflammatory reaction of microglia 
It was hypothesized that costunolide exerts its effects on the microglia by 




a)  Costunolide-PPARγ interaction was studied in BV2 microglial cells in 
vitro  
b) Effect of costunolide treatment on PPARγ expression was studied in 
activated microglial cells in vitro and in TBI rat models. 
 
1.8.2.2 To investigate if the mechanism of action of costunolide is via 
PPARγ receptor 
a)  Dominant negative (DN) PPARγ was transfected in BV2 microglia to 
mask the endogenous expression of PPARγ. 
b)  NFκB nuclear translocation was studied in activated BV2 microglia 
transfected with DN PPARγ following costunolide treatment. 
 
Overall, this study mainly focuses on the expression pattern and role of 
Runx1t1 in microglial cells and how it is regulated during microglial 
activation. This study also emphasizes on the mechanism of action and 
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2.1 Animals  
Wistar rats aged 1d, 3d, 5d, 7d, 14d, 21d, 28d and 3m were purchased from 
the Laboratory Animal Centre, National University of Singapore. All 
experiments were carried out in accordance with the International Guiding 
Principles for Animal Research, and approved by the National University of 
Singapore/Institutional Animal Care and Use Committee (IACUC), 
(NUS/IACUC/080/10) and DSO National Laboratories Institutional Animal 
Care and Use Committee (DSOACUC/10/107). All efforts were made to 
reduce the number and pain of rats used. The number of Wistar rats used in 
each experimental group is listed in Table1. 
 
Table 1. Wistar rats used in each experiment (Minimum 3 animals were 
used in each group) 
Age 
Total  
Number      Experiment 
 
1,3,5,7,14,21 & 28-
day  21    




5 day   10 
Control group and LPS treatment 
group  
 
28 day  12 
Control group and LPS treatment 
group  
 
3 day  80 Primary culture of microglia 
 
3 Months  35 Traumatic Brain Injury 
 
  TOTAL   number of animals used                      158 
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2.1.1 Drug treatment for animals 
2.1.1.1 Materials 
 Lipopolysaccharide (1mg/kg; Cat. No. L2654, Sigma-Aldrich, MO, 
USA) 
 Costunolide (Cat. No. 2483, Tocris Bioscience) 
 
2.1.2 Injection of lipopolysaccharide  
2.1.2.1 Procedure 
In the experimental groups, the rats (5 day and 4 weeks) were given an 
intraperitoneal (i.p.) injection of 100μL lipopolysaccharide (LPS, 1mg/kg 
diluted in 250μl of saline/injection). The rats were sacrificed at 3h after LPS 
injection; rats receiving an equal volume of saline served as age-matched 
controls. For immunostaining, the brains were removed and sectioned, and the 
tissue sections stored at -20°C until use. 
2.1.3 Injection of Costunolide 
2.1.3.1 Procedure 
Rats (3 months) after traumatc brain injury (TBI) were given an i.p. injection 
of costunolide [20 mg/kg of costunolide dissolved in DMSO/saline, (Eliza et 
al. 2009)]. The control groups were given equal volume of saline 
intraperitoneally. After 24h of treatment, the animals were perfused and the 
brain tissues were collected. 
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2.1.4 Surgical preparation for induction of Fluid Percussion Injury 
Rats weighing about 250-300g body weight were anaesthetized with an i.p 
injection of Xylazine (10mg/kg) and Ketamine (75mg/kg) cocktail prior to the 
surgery. The scalp was shaved and applied with povidine/iodine to prevent 
infection in wounds. The anesthetized animal was mounted and immobilized 
on a stereotaxic frame with blunt-tip ear bars. An incision was made 
longitudinally along the dorsal midline of the head using a sterilized scalpel. 
The scalp and temporal muscle were reflected using sterilized hemostats to 
expose the bregma and lambda of the brain. Using the bregma as a reference 
point, the guide cannula was lowered so that it was centered on the bregma. A 
~5mm hole was made at the bregma using a stereotaxic high-speed dental drill 
and the bone flap was removed. A modified cannula consisting of a head 
cannula and Female Luer-Lock were fixed firmly with dental cement over the 
hole and the Luer-Lock was twisted into place. 
 
2.1.4.1 Fluid Percussion Injury (FPI) 
The Lateral Fluid Percussion (LFP) device consists of a Plexiglas cylindrical 
reservoir filled with distilled water (See Fig. IV). One end of the reservoir has 
a Plexiglas piston mounted on O-rings and the opposite end has a transducer 
housed with a 2.6-mm inside diameter male Leur-lock opening. The pendulum 
was at 90
o
 perpendicular to the ground and just abuts the piston at resting 
position. The tubing from the percussion device was attached to the head 
cannula by twisting. The pendulum was released and allowed to fall freely to 
strike the piston. LFP produced a focal damage in the ipsilateral hippocampus 
and cerebral cortex by quickly injecting a small volume of saline epidurally, 
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which induces a brief deformation and displacement of neural tissue. An 
extracranial transducer was used to measure the pressure pulse in atmospheres 
(ATM) and recorded on a digital storage oscilloscope. The head cannula was 
then removed from the rat and the incision was closed with surgical staples. 
The animals were perfused twenty four hours post LFP, and the brain tissues 
were collected. Sham-operated animals received similar anaesthesia and 
surgery, but were not subjected to trauma treatment. 
 
 
Fig. IV. The image shows an LFP instrument which consists of a cylindrical 
reservoir filled with distilled water, a pendulum (which can be released from a 
precalibrated angle), a stage for positioning the rats, and a signal conditioner 
for pressure measurement [Adapted from (Kabadi et al. 2010)]. 
 
2.1.5 Perfusion of Wistar rats 
2.1.5.1 Principle 
The transcardial perfusion using aldehyde-based fixatives is an effective 
paradigm for preserving the soft issues. Rapid and comprehensive fixation of 
Impactor  
assembly 





Output to signal  
conditioner 
Positioning site 
for the animal 
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tissues (brain) is essential for histological, anatomical and molecular analyses. 
In transcardial perfusion, the animals are anaesthetized and fixed with fixative 
which is pumped from the heart to the entire body including brain (Jamur & 
Oliver 2010, Paul et al. 2008). 
 
2.1.5.2 Materials 
 0.1M Sodium dihydrogen phosphate (Cat. No. 131965.1211,  Panreac 
AppliChem, Spain) 
 0.1M di-sodium dihydrogen phosphate (Cat. No. 28029.292, VWR 
International, USA) 
 Paraformaldehyde (PF) (Cat. No.P001, TAAB Laboratories, UK) 
 
2.1.5.3 Procedure for transcardial perfusion 
Wistar rats aged 1, 3, 5, 7, 14, 21, 28d and 3m were used for perfusion (n=3, at 
each age). The Wistar rats were anesthetized with Xylene-Ketamine cocktail 
(60 mg/kg) and perfused transcardially with pre-perfusion buffer, the Ringer’s 
solution and 2% PF in 0.1 M phosphate buffer.  
In order to make 1000ml of 0.1M phosphate buffer, 800ml of 0.1M 
disodium hydrogen phosphate was slowly added to 200ml of 0.1M sodium 
dihydrogen phosphate and stirred constantly until the pH
 
was reached 7.4.  
2% PF was prepared by dissolving 20g of PF to 1000ml of phosphate 
buffer. Ringer's solution (saline) and PF were filled in the separate bottles and 
appropriate needle was attached to end of the tube. The rats were 
anaesthetized and placed on the operating table with its back down. The 
appendages of the rats were securely pinned. Surgical instruments including 
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scissors, forceps and clamps were used to dissect the animals. Depth of 
anesthesia was determined by using pinch-response method. Once the animal 
was fully anaesthetized, an incision was made with scalpel through its 
abdomen up to the diaphragm and the connective tissues were removed to get 
access to the rib cage. Large scissors were used to cut through ribs. Two end 
horizontal cuts were made through the rib cage to open up the thoracic cavity. 
Forceps were used to hold the heart steady and the perfusion needle was 
inserted directly into the left ventricle. Buffer valve was then released to allow 
slow and steady flow of 0.9% saline solution for around 20 ml/min. The right 
atrium was cut with a fine scissor to ensure the free flow of solution. The 
blood was completely cleared and the liver appeared pale (which is an 
indication of a good perfusion). The valve was changed to allow 2% PF 
solution (250-300 ml). After 30-45 minutes of perfusion the brain tissue was 
excised using scalpel and forceps. Tissues were then placed in a vial 
containing the same fixative for 2 -3hours on ice or at 4⁰C before proceeding 
to cryoprotection in 15% sucrose solution overnight.  
 
2.1.6 Histology 
2.1.6.1 Preparation of gelatin coated slides 
 Gelatin (Merck, Germany) 
 Distilled Water- 600ml 
 Chrome alum (Chromium (III) Potassium Sulphate) (Merck, Germany) 
 




For making gelatin solution, 9g of gelatin was added to 600ml of distilled 
water and the solution was stir heated until the gelatin was dissolved 
completely. Chrom alum (0.9g) was added into this solution. The sterile slides 
were dipped into this solution for 1min and dried inside the fume hood. The 
gelatin-coated slides were stored in a 37°C incubator. 
 
2.1.7 Cryosectioning of brain  
2.1.7.1 Materials 
 Shanton M+ embedding matrix (Thermo Scientific, Cat. No. 1310, 
USA) 
 Brush 
 Cryostat (Leica-Microsystems, Leica CM 3050, Germany) 
 Gelatin coated slides 
 
2.1.7.2 Procedure  
A metal chunk was coated with embedding matrix and immersed into liquid 
nitrogen until it gets frozen to a semi-solid state. Fixed and dehydrated brain 
tissue samples were placed on top of the metal chunk containing the semi-
solid embedding matrix and were fully covered with fresh embedding matrix. 
It was then immersed into liquid nitrogen rapidly to freeze the tissue samples. 
The metal chunk containing frozen tissue samples were then placed into the 
cryostat for sectioning. An object temperature (OT) of -10°C and chamber 
temperature (CT) of -15°C were maintained throughout the procedure. The 
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brain tissue was sectioned coronally at 30μm thickness through the corpus 
callosum (CC) and hippocampus. The sections were mounted on a gelatin 
coated slides for immunostaining and stored at -20°C. 
2.1.8 Alzheimer’s rat brain model 
2.1.8.1 Materials 
 Tissue processor (Model ATP700, Histo-Line laboratories, Italy) 
 Microtome (Model Leica RM 2165, Germany) 
 
2.1.8.2 Procedure for sectioning of AD rat brain tissue 
Brain tissues of Samaritan Alzheimer’s Disease rat model fixed with 10% 
formalin were kindly gifted by Taconic, USA. According to Taconic, 
Alzheimer's disease was induced in the rat by slow release of L-Buthionine-
(S,R)-sulfoximine, ferrous sulfate heptahydrate and Beta-Amyloid (1-42) 
peptide into the lateral ventricle of the brain. The brain tissue was paraffin-
embedded on a tissue processor and sectioned on a microtome at 7µm 
thickness. The sections were collected on gelatin-coated slides for 
immunofluorescence analysis.  
 
2.2 Cell Culture 
2.2.1 Primary microglial culture 
2.2.1.1 Materials 
 Antibiotic antimycotic solution (100X) (Sigma-Aldrich, USA, Cat. No. 
A5955) 
 DMEM medium (, Invitrogen, USA, Cat. No. 11966025) 
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 Insulin (Sigma-Aldrich, USA, Cat. No. I0516) 
 Fetal bovine serum (FBS, Cat. No. 10099, Invitrogen, USA)   
 Non-essential amino acid (Cat. No. 11140050, Invitrogen, USA)  
 70µm Nylon Mesh (BD Biosciences, USA, Cat. No. 352350) 
 Deoxyribonuclease (Cat. No. D4527, Sigma-Aldrich, USA) 
 75cm2  tissue culture flasks (NUNC, Denmark) 
 OX-42 (mouse monoclonal IgG, Cat. No. CBL1512, Chemicon, USA) 
 Lycopersicon esculentum (tomato) lectin (Cat. No. L0401, Sigma-
Aldrich, USA) 
 Trypsin and EDTA (10X) (Invitrogen, USA, Cat. No. 15400-054) 
 
2.2.1.2 Procedure 
2.2.1.2.1 Isolation of brain tissue 
3d old rat pups were anesthetized with pentobarbitone (50mg/kg) and the 
heads were wiped with 75% ethanol. An incision was made through the skin 
along the midline in a caudal to rostral direction to expose the skull. Further, 
the skull was cut mediolaterally and then in a rostral direction from the 
original point of incision, thus removed the two rectangular flaps of the skull. 
The brain tissue was scooped out using a pair of curved forceps and was 
placed it on to a dish containing cold PBS. The unwanted brain regions were 
removed and the tissue was dissected finely to remove the meninges. Then it 
was transferred to 10ml DMEM medium. 
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2.2.1.2.2 Mechanical dissociation and enzymatic digestion of brain tissue 
      A pair of forceps was used to chop off the tissue gently in the dish with an 
up-and-down motion. The fine pieces of brain tissue were collected and a 
10ml plastic pipette was used to mechanically dissociate the brain tissues by 
pipetting in and out in a 50-ml sterile tube on ice. 
      100μl of DNase solution (50μg/ml DNase) and 1ml of Trypsin-EDTA 
solution (0.5mg/ml) were added into the dissociated brain tissue in 50ml tube 
and mixed well. The solution was then transferred to a culture flask and  
placed in a shaker for 15 min at 37°C and shaken at 250strokes. The cells were 
filtered using cell strainer and then the cell suspension was transferred to a 
50ml centrifuge tube for centrifugation at 1000rpm for 5 min. The cells were 
then seeded (1.2×10
6
 cells/ml) in a culture dish containing medium with 10% 
FBS and cultured in a CO2 incubator at 37°C. Medium was changed every 2-3 
days until the confluency was achieved in 10-14 days. 
2.2.1.2.3 Purification of microglial cells 
The mixed glial cultures were purified after 10-14days of culturing, microglial 
cells were isolated (Saura et al. 2003). Briefly, the mixed glial cultures were 
washed with PBS two times and incubated with trypsin solution containing 
0.5M EDTA (20μl) and 0.25% trypsin (1ml) diluted in 40 ml of DMEM for 
15min. The upper layers of the cells were detached from the surface and were 
removed. The microglial cells remained attached to the bottom of the flask. 
These cells were cultured in complete medium (DMEM containing antibiotics 
and 10% FBS).  
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The purity of microglial cells were assessed immunohistochemically using 
OX42 (1:200), a marker for microglia and the purity of microglial culture was 
found to be around 95%. 





flask.  For immunocytochemistry, cells were plated on a 24 well 
culture dish (2.5×10
5
 per well) and incubated at 37°C in a 5% CO2 incubator 
for 24h.  
 
2.2.2 BV2 Microglial culture 
2.2.2.1 Materials 
 Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, USA, Cat. 
No. 11966025) 
 Trypsin-EDTA (TE, 10X) (Cat. No. 15400-054, Invitrogen, USA) 
 Lipopolysaccharide (LPS) (Cat. No. L2762,Sigma-Aldrich, USA) 
 Sodium Butyrate (Cat. No.30,341-0, Sigma-Aldrich, USA) 
 Fetal bovine serum (FBS, Invitrogen, USA, Cat. No. 10099)   
 0.1M phosphate-buffered saline (Vivantis, Malaysia, Cat. No. PB0344) 
 
2.2.2.2 Procedure 
Murine BV2 microglial cell line (Huo et al. 2011, Nayak et al. 2010, Bocchini 
et al. 1992) was  cultured in 75 cm
2 
culture flasks containing DMEM 
supplemented with 1% antibiotic antimycotic solution and 10% FBS, at 37ºC 
in 5% CO2 and 95% air incubator. Once the cells attained complete 
confluency, TE working solution (1ml of TE in 9ml PBS), was added to the 
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flask to harvest the cells. For subculturing, complete-medium (10ml) was 
added to TE and the cell suspension was collected in a 50ml tube for 
centrifugation at 1000rpm for 5min at 4°C. After centrifugation, the 
supernatant was removed and the pellet was then re-suspended in 10 ml 
complete medium. Hemocytometer was used to count the cells and the cells 
were then seeded in a new culture flask.  
For experiments, cells were plated on 96-well plates at about a density 




 for RNA isolation, and at 2.0 × 10
5
 per well on a 24-
well plate for immunocytochemistry. On the following day, cells were plated 
on poly-L-lysine coated coverslips in 24 well plates and incubated with either 
LPS (1μg/mL) for 3h or HDAC inhibitor (5mM sodium butyrate) overnight 
(Hagopian et al. 1977). In HDAC+LPS treatment groups, the cells were pre-
treated with HDAC inhibitor overnight before LPS treatment. The complete 
medium was replaced with basic medium for LPS treatment. The cells 
cultured in the basic medium served as the control. The time point (3h) and  
dosage (1μg/ml) of  LPS treatment have been chosen based on results obtained 
from MTS assay and previous reports  (Nakamura et al. 1999, Nayak et al. 
2010). 
 In order to study the effects of costunolide and LPS on microglial cells, 
the cells were incubated either with costunolide (1μM) or LPS (1μg/ml) or 
LPS plus costunolide. Effect of costunolide was studied by adding costunolide 
(1uM) 30 minutes prior to the addition of LPS in microglia cells. In all the 
experiments, control cells were treated with DMSO as the vehicle. 
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2.2.3 Cytotoxicity assay (MTS assay) 
2.2.3.1 Principle 
MTS assay (CellTiter 96 Aqueous One Solution assay) is a colorimetric assay 
to determine the cell viability. The kit contains an electron coupling reagent 
(phenazine ethosulfate; PES) and 3-[4,5-dimethylthiazol-2-yl]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt, MTS. In 
this assay, cells bioreduced the MTS tetrazolium compound into a colored 
formazan product which is soluble in culture medium. This conversion is 
mediated by NADPH or NADH produced by the dehydrogenase enzyme in 
the active cells. Measuring the quantity of this formazan product at 490nm 
absorbance is directly proportional to the number of viable cells in the culture 
(Cory et al. 1991). 
 
2.2.3.2 Material 
 CellTiter 96 Aqueous One Solution Kit (Cat No. G3582, Promega, 
USA) 
2.2.3.3 Procedure 
BV2 cells were seeded on a 96-well plate (5000 cells/well) containing 100μl 
culture medium and treated with different concentrations of LPS (0.1μg/ml -
10μg/ml) at 37°C for 1-6h. MTS reagent (20μl/well) was added to the culture 
and incubated at 37°C for 1-4h. The absorbance was recorded at 490nm using 
a microplate reader (Spectramax M5, Molecular Devices, USA) 
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2.2.4 Immunofluorescence analysis 
2.2.4.1 Principle 
Fluorescence is a process where fluorochrome dyes absorb ultra violet rays 
and emit visible light (Valeur & Berberan-Santos 2011). Immunofluorescence 
is a staining technique used to demonstrate antigen-antibody reaction. 
Antibodies are labeled with a fluorescent dye and antigens within the cell are 
visualized using these antibodies as fluorescent probes via a fluorescent 
microscope (Fritschy & Härtig 2001). There are mainly 2 types of 
immunofluorescence techniques, primary/direct immunofluorescence and 
secondary/indirect immunofluorescence. Direct immunofluorescence 
technique uses a single fluorescent-labeled antibody which can bind to the 
target molecule which can be detected by fluorescent microscopy.  Indirect 
method uses two antibodies; one is an unlabeled primary antibody and another 
one is a fluorescent labeled secondary antibody. The primary antibody will 
bind with its target molecule and the secondary antibody with fluorescent tag 
binds with the primary antibody.  
  The procedure of immunofluorescence includes fixation, blocking, 
incubation with primary and secondary antibodies and visualization of 
antigen-antibody complex using microscope. Fixation is required to stabilize 
the cells or tissues from the subsequent processing and staining. Blocking is 
used to remove non-specific background staining which improves the primary 
antibody specificity (Rizzetto et al. 1977).  
 




 Mouse anti-OX-42 (1:100, mouse monoclonal IgG, Cat. No. 
CBL1512, Chemicon, USA)  
 Rabbit anti-Runx1t1 (1:100, rabbit polyclonal, Cat.No.sc-28693, Santa 
Cruz, USA)     
 Rabbit anti-LAT2 (1:100, Cat No. sc-133726, Santa Cruz 
Biotechnology, USA) 
 Rabbit anti-H3 acetylated (Lys9/14) (1:100, Cat No. 17-615, Millipore, 
USA) 
 Rabbit anti-MKP-1 (1:200; Cat No. sc-1102, Santa Cruz 
Biotechnology, USA) 
 Rabbit anti PPARɣ (1:200, Cat No. sc-7196, Santa Cruz 
Biotechnology, USA)  
 Rabbit NFκB (1:200, rabbit polyclonal, sc-109, Santa Cruz 
Biotechnology, USA)  
 Rabbit TNF-α (1:200, rabbit polyclonal, Cat. No. AB1837P) 
 Rabbit anti-Sphk1(1:200, rabbit polyclonal, Cat. No. sc-48825, Santa 
Cruz, USA) 
 FITC-conjugated goat anti-mouse IgG (Millipore, USA, 1:200, Cat No. 
5024)  
 4’, 6- diamidino-2-phenylindole dihydrochloride (DAPI) (Molecular 
Probes, USA, Cat. No. D1306) 
 Cy3-conjugated sheep anti-rabbit IgG (Sigma-Aldrich, USA, 1:200, 
Cat No. C2306) 
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 4% paraformaldehyde (PF) 
 Phosphate Buffered Saline (10X PBS) (Invitrogen, USA, Cat. No. 
14200166) 
 Fluorescent Mounting Medium (DAKO, Denmark, Cat. No. S302380) 
 0.1M phosphate-buffered saline (PBS) 
 Confocal microscope (LSM FV1000; Olympus, Tokyo, Japan).  
 
2.2.4.3 Procedure for double immunofluorescence staining of rat brain 
tissue 
The brain sections were washed and incubated with normal goat serum (NGS, 
5%) at room temperature for 1h (n=3). In the next step, the tissue sections 
were incubated with a mixture of primary antibodies containing anti-OX-42 
and anti-Runx1t1 or anti-LAT2 or anti-PPARɣ or anti-NFκB or anti-TNFα, or 
anti-Sphk1 and anti-MKP1 at room temperature overnight. The, the sections 
were washed next day and incubated with a mixture of secondary antibodies: 
FITC-conjugated goat anti-mouse IgG and Cy3-conjugated sheep anti-rabbit 
IgG for 1h. Subsequently, the brain tissue sections were stained with 4', 6-
diamidino-2-phenylindole (DAPI, 1 μg/mL) at room temperature for 5min. 
After PBS wash, the tissue sections were mounted with a fluorescent mounting 
medium. The tissue sections were then viewed under a confocal microscope.  
2.2.4.4 Immunofluorescence staining of microglial cells 
Primary microglial cells or BV2 microglial cells were plated onto cover slips 
coated with poly-L-lysine in a 24-well plate. For immunofluorescence 
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analysis, the cells were subjected to different treatments and fixed with 4% PF 
in phosphate buffer for 30min at room temperature (number of biological 
samples, n=3). The cells were then incubated with 5% goat serum for 1h.  
Coverslips containing adherent cells were incubated with primary antibodies 
containing OX-42 (1:200) with anti-Runx1t1 (1:100), or anti-LAT2 (1:100), or 
anti-H3 acetylated(Lys9/14) (1:100) or anti-PPARɣ (1:100) and anti-NFκB 
(1:100) at 4°C overnight. The coverslips were washed with PBS for three 
times and incubated with FITC-conjugated goat anti-mouse IgG (1:200), or 
FITC-conjugated lectin (1:300), or Cy3-conjugated sheep anti-rabbit IgG 
(1:200) for 1h at room temperature. The cell nuclei were counterstained with 
DAPI (1μg/mL) for 5min. Coverslips were then washed with PBS and a 
fluorescent mounting medium was used to mount the cells and a confocal 
microscope was used to capture the images.  
2.2.5 RNA extraction and real-time quantitative reverse transcription 
polymerase chain reactions (qRT-PCR) 
2.2.5.1 Principle 
Polymerase chain reaction (PCR) is a technique developed by Kary Mullis in 
1980s to amplify specific regions of DNA using DNA polymerase and a 
primer (Mullis et al. 1987). It requires a primer to start with since DNA 
polymerase can add nucleotide only to the pre-existing 3’-OH group. This 
helps the researchers to amplify a specific region of the template DNA strand. 
Quantitative real time RT-PCR (qRT-PCR) is used to amplify specific cDNA 
regions using specific reverse and forward primers and quantitatively measure 
the amplified DNA using fluorescent probes. qRT-PCR consists of three steps 
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including denaturation, annealing and extension or elongation. The DNA-
binding fluorescent dye (SYBR green) binds to the minor groove of double-
stranded DNA during denaturation. Denaturation at a high temperature allows 
the double stranded DNA to split into two single stranded DNA templates. 
The unbound dye at this stage emits fluorescence. Lowering temperature to a 
particular level helps annealing of the primer to the denatured DNA template. 
The designed primers are complementary to the specific DNA regions which 
represents the target gene. During amplification, the Taq DNA polymerase 
enzyme starts extending specific region of template DNA from the 3’ end of 
the primer by adding dNTPs which are complementary to that particular 
region. During this extension stage, the amount of fluorescent dye binding to 
the newly formed double-stranded DNA increases and this leads to an 
increased fluorescence signal. The amount of amplified DNA template can be 
detected by measuring the numerical value obtained from fluorescent intensity 
called cycle threshold (Ct) value (Bustin 2000).  Sufficient copies of cDNA 
are made after several cycles of amplification. The fold change of relative 
expression of a gene of interest in experimental group vs control group is 
calculated by the 2
-ΔΔCt 
method (Livak & Schmittgen 2001). The data is 
normalized with endogenous reference gene (β actin) before calculating the 




 RNeasy mini kit (Cat. No. 74106, Qiagen, Germany) 
 β-mercaptoethanol (Cat. No. 436022A, VWR International, USA) 
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 Molony murine leukemia virus reverse transcriptase (Cat. No. M1701, 
M-MLV, Promega, USA) 
 Spectrophotometer (Thermo Scientific, USA, Nanodrop; Model No. 
ND1000) 
 dNTP mix (Promega, USA , Cat. No. U1240) 
 RNase inhibitor (Cat. No. N2111, Promega, USA) 
 Oligo(dT) primer (Applied Biosystem, USA, Cat. No. 4306737) 
 MicroAmp® optical 96-well plate (Applied Biosystems, USA, Cat. 
No. 4306737) 
 Fast SYBR® green master mix (Applied Biosystems, USA, Cat No. 
4385612) 
 QuantiTect SYBR Green PCR Kit (Cat. No.204141, QIAGEN, USA) 
 Fast real-time PCR system (Applied Biosystems, Model No. 7900HT, 
USA) 
 
2.2.5.3 Procedure for total RNA isolation 
The total RNA was extracted from primary microglial cells and BV2 
microglial cells subjected to various treatments (LPS, HDACi, scrambled and 
Runx1t1 siRNA transfection) using RNeasy Mini kit (Qiagen, Valencia, CA, 
USA). In the first step following various treatments to microglial cells, RLT 
lysis buffer was prepared by adding 10μl of β-mercaptoethanol per ml of RLT 
buffer. 600μl RLT lysis buffer was added to each well of a 6 well plate 
containing cells. Cell scraper was used to scrap cells and lysate was 
transferred to a 1.5ml microfuge vial. 1ml syringe was used to homogenize the 
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lysate thoroughly by sucking in and out the lysate. In the next step, 70% 
ethanol was added to the cell lysate and was transferred to the RNeasy spin 
column and centrifuged at 10000rpm at room temperature for 1min. In the 
subsequent steps, RW1 and RPE buffers were added to the spin columns to 
remove the unwanted materials and flow-through was discarded after each 
step. In the final step, 20μl of nuclease free water was added to the spin 
column to elute the bound RNA. RNA concentration was quantified with a 
spectrophotometer. 
 
2.2.5.4 Procedure for reverse transcription of RNA to cDNA 
Reverse transcription was carried out as follows: 1μl of oligodT primer 
(500μg/ml) was mixed with 2μg of total RNA in a microcentrifuge tube and 
the mixture was heated at 70°C for 5min. Then the tube was immediately 
placed on ice for 5min. The reaction mixture was prepared by adding 0.5μl of 
deoxyribonucleotide triphosphate mix (dNTP, 25μM,), 1μl of M-MLV reverse 
transcriptase enzyme (10000u) and 0.7μl of RNAse inhibitor (2500u). The 
total volume was made up to 25μl with RNAse-free water and then incubated 
for reverse transcription of RNA to cDNA at 42°C for 1h. A final incubation 
was made at 95°C for 5min to stop the reaction and the cDNA product was 
stored at -20°C. 
 
2.2.5.5 Procedure for real time quantitative RT-PCR 
 RT-PCR was carried out according to manufacturer’s instructions on an 
Applied Biosystems 7900HT thermal cycler instrument using 
QuantiTect/FAST SYBR Green PCR Kit. For RT-PCR, reaction mixture 
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containing 5μl of QuantiTect/Fast SYBR Green PCR Master Mix, 1μl of 
10μM forward primer, 1μl of 10μM reverse primer (Table 2), RNAse-free 
water and cDNA samples was prepared and added into 96 well plates. The 
PCR was performed by  an initial denaturation (95°C for 15min), followed by 
45 cycles of denaturation (94°C for 15s), annealing (60°C for 25s) and a  final 
extension (72°C for 12s). The target gene expression (Runx1t1, cdk4, LAT2) 
was measured and normalized to βactin (internal control) in triplicate (n=3). 
Ct values, melting and amplification curves were displayed and were used to 
calculate relative gene expression.  Fold change of target genes’ expression 
was calculated using the following formula: fold change = 2
-[[Ct (control) gene X-Ct 
(control) actin][Ct (activated) gene X-Ct (activated) actin]] 
(Livak & Schmittgen 2001). 
Table 2. Primer sequences used for RT–PCR 
Genes Sense Antisense Size 
(bp) 
Runx1t1 ACGAACAGCTGCTTCTGGAT TGCTTGGATGTTCTGAGTGC 153 
Cdk4 CAGGCCGCTTAGAAACTGAC CAATGTTGTACGGCTGATGG 178 
m βactin GGATTCCATACCCAAGAAGGA GAAGAGCTATGAGCTGCCTGA 103 








CCTCTGCGCCCTTGAGCTAGGA CACAAGAAGATGCGGCCGTCTC 158 
Runx1t1 
siRNA 
GCAUCUCGAUCAUCUGUUA UAACAGAUGAUCGAGAUGC  









GGUGAACUCUACUUUGACA UGUCAAAGUAGAGUUCACC  
 
2.2.6 Detection of PCR products using agarose gel electrophoresis  
2.2.6.1 Principle 
Agarose gel electrophoresis (AGE) is an electrophoresis method used to 
separate proteins or DNA based on the charge and size in an agarose matrix by 
applying an electric field. DNA has negative charge and runs through the gel 
matrix towards the positive electrode. The molecules with larger size run slow 
and molecules with smaller size run faster and tend to be closer to the positive 
electrode. Ethidium bromide which intercalates with the DNA and can be 
viewed under UV light was also added in the gel. 
 
2.2.6.2 Materials  
 Agarose powder (Sigma- Aldrich, Cat.No. A2790, USA) 
 DNA loading dye (6X) (Promega, Cat. No. G1881, USA) 
 Ethidium Bromide (Cat. No. 161-0433, Bio-Rad, USA) 
 DNA ladder 100bp (Promega, Cat. No. G6951, USA) 
 GeneGenius (Syngene, UK) 
 Tris acetate EDTA buffer (TAE) (Cat. No. 15558034, Invitrogen, 
USA) 




The RT-PCR products size was determined by using agarose gel 
electrophoresis. 2% agarose gel was prepared by heating 2g of agarose in 
100ml TAE buffer. 5μl of ethidium bromide was added into the agarose 
solution which was poured onto a gel tray. Gel comb was placed immediately 
onto the gel to form wells. 10μl of RT-PCR product was mixed with 2μl of 
loading dye and loaded onto the wells in the gel.  10μl of 100bp DNA ladder 
was loaded in one of the wells and the samples were electrophoresed at 100v 
for 45min in TAE buffer. The separated DNA in the gel was visualized in a 
UV trans-illuminator and photographed using ChemiGenius2 image analyzer. 
The size of the amplified DNA (from 100 to 1000bp) was determined using 
100bp DNA ladder. Single band and predicted size confirmed that the primers 
used were specific. 
2.2.7 Western blot assay 
2.2.7.1 Principle 
Western blot, also known as protein immunoblotting described first in 1979 
(Towbin et al. 1979), is used to detect specific proteins based on their ability 
to bind to specific antibodies. It involves two steps, SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and protein blotting. SDS-PAGE is used to 
separate the denatured proteins (in the length of a polypeptide) in the given 
samples. The separated proteins are then transferred on to a polyvinylidene 
fluoride (PVDF) or nitrocellulose membrane and stained with specific 
antibodies which detect the protein of interest in the given sample. Secondary 
antibodies conjugated with horseradish peroxide (HRP) raised against primary 
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antibody emits signal upon treatment with chemiluminiscent substrate 
(Towbin et al. 1979). Due to the high resolution of SDS-PAGE and strong 




 Protein assay dye reagent (Bio-Rad, Cat. No. 5000006, USA) 
 Mammalian protein extraction reagent (M-PER) (Thermo Fisher 
Scientific, Cat. No. 78501, USA)  
 Microplate reader (Spectramax M5, Molecular Devices, USA) 
 Protease inhibitor (Thermo Fisher Scientific, Cat. No. 88665, USA)  
 
10% resolving gel (10ml) 
H2O     4.0ml 
30% acrylamide mix   3.3ml 
1.5 M Tris (pH 8.8)   2.5ml 
10% SDS    0.1ml 
10% ammonium persulfate            0.1ml 
TEMED    0.004ml 
 
5% stacking gel (5ml) 
H2O     3.4ml 
30% acrylamide mix   0.83ml 
1.0 M Tris (pH 6.8)   0.63ml 
10% SDS    0.05ml 
10% ammonium persulfate             0.05ml 
TEMED    0.005ml 
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 Blotting paper (Bio-Rad, USA, Cat. No. 88605) 
 Precision Plus Standard protein marker (Kaleidoscope) (Cat. No. 161-
0375, Bio-Rad, USA) 
 Trans blot SD semi-dry electrophoretic transfer cell (Bio-Rad, USA) 
 PVDF membrane (Thermo Scientific, USA, Cat. No. 88520) 
 
Buffers 
Running buffer- 10X Tris/glycine/SDS electrophoresis buffer (Bio-Rad, USA, 
Cat No. 161-0732) 
Transfer buffer- Tris/glycine electrophoresis buffer (Bio-Rad, USA, Cat. No. 
161-0734) 
Laemmli protein loading buffer (2X) (Bio-Rad, USA, Cat No. 161-0737) 
 
1X TBS (pH 7.6) 
Tris base   2.42 g 
NaCl    0.8 g 
Deionized water up to 1000ml; adjusted pH 7.6 with 2N HCL 
1X TBST 
 1X TBS                    1000ml 
 10% Tween 20          10ml 
 Blotting grade dry milk (Bio-Rad, USA, Cat. No. 170 6404) 
 Rabbit anti-Runx1t1, (1:500, Cat.No.sc-28693, Santa Cruz, USA) 
 Rabbit anti-LAT2 (1:500, Cat No. sc-133726, Santa Cruz 
Biotechnology, USA) 
 Rabbit anti-cdk4 (1:500, Cat. No sc-260 Santa Cruz, USA) 
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 Rabbit anti-Sphk1 (1:1000, rabbit polyclonal, Cat. No.sc-48825, Santa 
Cruz, USA) 
 Goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) 
(Chemicon International, USA, secondary antibody (1:5000), Cat. No. 
AP308P) 
 Goat anti-rabbit IgG conjugated with horseradish peroxidase (HRP) () 
(Chemicon International, USA, secondary antibody (1:3000), Cat. No. 
AP307P) 
 Mouse anti- β-actin monoclonal antibody (Sigma-Aldrich, USA, 
1:5000, Cat. No. A1978) 
 CL-Xposure film (Thermo Scientific, USA, Cat. No. 34091) 
 Densitometer (Model No. GS-800, Bio-Rad, USA) 
 Stripping buffer (Cat. No. 46430, Thermo Scientific, USA) 
 SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, USA, Cat. No. 34087) 
 
2.2.7.3 Procedure for total protein extraction and quantification 
BV2 microglial cells were seeded on a 6 well plate and exposed to different 
treatments.  Total protein of BV2 microglial cells was extracted separately 
using the Protein Extraction Kit.  200μl of mammalian protein extraction 
reagent (MPER) containing protease inhibitor cocktail was added to lyse the 
cells. The lysed cells were scrapped and centrifuged at 13,000rpm for 20min at 
4°C. The supernatant containing protein lysate was collected and stored at -
80°C. The protein level was quantified using Bradford calorimetric assay 
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(Bradford 1976). The calorimetric assay is based on maximum observed shift 
in the absorbance when Coomassie Brilliant Blue G-250 dye reacts with 
protein. There is variation in the color response of Coomassie Brilliant Blue to 
different proteins. This variation in color depends on the concentration of 
proteins. Protein concentration can be detected by measuring the absorbance at 
595nm. Serial dilution of standard protein was used to plot standard curve. 
The unknown protein sample concentration was analyzed by extrapolation 
method. 10μl of unknown protein sample and 200μl of assay reagent was 
added to the wells of a 96-well plate and absorbance was taken at 595nm using 
a microplate reader. Actual protein concentration in ‘mg’ was then calculated 
based on the absorbance value. 
2.2.7.4 Procedure for Sodium dodecyl sulfate-Polyacrylamide gel 
electrophoresis (SDS-PAGE) and protein detection 
Twenty µg of each protein sample to be loaded was prepared by adding 6X 
protein loading dye and heated for 5min at 95°C for denaturation. These 
protein samples were separated on SDS-polyacrylamide gels containing 10% 
resolving gel and 5% stacking gel along with a protein marker at 100 volts for 
2h. Once the proteins were separated, they were transferred to polyvinylidene 
difluoride transfer membranes (PVDF). Prior to transfer, PVDF membrane 
was immersed in methanol for 1min and washed with distilled water in order 
to activate it. A blotting paper was placed on top of the transfer instrument and 
PVDF membrane was placed on top of it followed by the gel and another 
blotting paper and transfer was carried out at 20 volts for 1h. Once the transfer 
is done, the membranes were blocked with dry milk (5%) and incubated 
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overnight with primary antibodies at 4°C . The primary antibodies used are: 
rabbit anti-Runx1t1, (1:500), rabbit anti-LAT2 (1:500), rabbit anti-cdk4 
(1:500), anti-SphK1(1:1000) and mouse anti-β-actin monoclonal antibody. 
The membranes were then washed with TBST (10min per wash) and 
incubated with horseradish peroxidase-conjugated secondary antibody at room 
temperature for 1h. The membranes were washed with TBST once and TBS 
twice, incubated with chemiluminiscent substrate for 5min and developed on a 
film. Densitometer was used to quantify the optical density of each protein 
band. Each protein band density was normalized with the respective β-actin 
density (n=3). 
2.2.8 Knockdown of Runx1t1 in BV2 microglial cells by siRNA 
2.2.8.1 Principle 
Small interfering RNA (siRNA) also known as silencing RNA or short 
interfering RNA which exerts gene silencing by degrading target mRNA 
(Ramaswamy & Slack 2002). They are double stranded RNA with 20-25 base 
pairs in length. siRNA is synthesized from small hairpin RNAs or from long 
dsRNAs via an enzymatic cleavage by Dicer. A synthetic siRNA with 
complementary sequence can be used to knockdown gene targets. The double 
stranded siRNA splits into two separate strands once transfected into the cell. 
One strand is attached to the RNA-induced silencing complex (RISC) which 
directs the siRNA to its target gene. Once it is bound to its complementary 
target mRNA, RISC induces degradation by its exonuclease activity, 
eventually preventing translation (Hannon 2002). 
 




 CY3-conjugated GAPDH siRNA (Ambion, USA, Cat No. AM4649) 
 Silencer select negative control siRNA (Ambion, USA, Cat No. 
4390843) 
 Silencer select pre-designed Runx1t1 siRNA (Ambion, USA, Cat No. 
4390771) (siRNA sequences are provided in Table-2)  
 RNAiMAX Lipofectamine transfection agent (Cat No. 13778-150, 
Ambion) 




Expression of Runx1t1 in BV2 microglial cells was inhibited using specific 
siRNA. Pre-designed Runx1t1 siRNA and Scrambled siRNA were obtained 
from Ambion (Table 1). BV2 microglial cells were transfected with siRNA 
according to the manufacturer’s instruction. BV2 microglial cells were 
suspended in OPTIMEM medium at a concentration of 2x10
5
 cells/ml. 
Transfection complexes were prepared by mixing 7.5μl of RNAiMAX 
Lipofectamine transfection agent  and 20nM siRNA in 500ml OPTIMEM 
Serum-free Medium for each well of a 6 well plate. This helps the siRNA to 
bind to the lipofectamine and facilitate its entry into the cells. 2x10
5
 cells were 
then seeded on to these transfection complexes, mixed gently, made up the 
total volume to 2.5ml with OPTIMEM and incubated for 24h in 6-well (2x10
5
 
cells/well) or 24-well (4x10
4
 cells/well) plates. CY3-conjugated GAPDH 
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siRNA was transfected with BV2 microglia and was viewed under fluorescent 
microscope to determine the transfection efficiency. Total RNA was extracted 
from the transfected cells after 24h of knockdown and qRTPCR was 
performed to determine the knockdown percentage. Runx1t1 protein 
expression in transfected BV2 microglial cells was analyzed by using western 
blot and immunofluorescence (n=3).  
 
2.2.9 BrdU incorporation assay in BV2 microglial cells 
2.2.9.1 Principle 
Bromodeoxyuridine (BrdU), an analog of thymidine, used to assess the 
proliferative state of cells. When cells are cultured with BrdU, it is 
incorporated into the DNA strands of the proliferating/dividing cells. The 
incorporated BrdU can be detected by using anti-BrdU antibody. This will 
provide information about cell proliferation rate, more specifically the number 
of cells that are synthesizing DNA in the S phase (Falini et al. 1988, 
Williamson et al. 1993). 
 
2.2.9.2 Materials 
 5-bromo-2-deoxyuridine (BrdU) (Cat. No. B5002, Sigma-Aldrich, 
USA) 
 Lycopersicon esculentum (tomato) lectin (1:100, Sigma-Aldrich, USA, 
Cat. No. L0401) 
 Mouse anti-BrdU monoclonal antibody (1:1000, , Sigma-Aldrich, 
USA, Cat. No. B2531) 
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Microglial cells were transferred onto poly-L-lysine-coated coverslips in 24-
well plates. The cells subjected to different treatments (Runx1t1 siRNA and 
HDACi, n=3) were incubated with BrdU (10µmol/l) for 2h and fixed with 4% 
PF for 20min at room temperature. Subsequently cells were treated with 2N 
HCl at 37ºC for 30min and blocked with normal goat serum (5%) for 30min, . 
After blocking, the cells were incubated with anti-BrdU monoclonal antibody 
(Cat No. B-2531, Sigma, USA) overnight at 4ºC. Further, the cells were 
incubated with goat anti-mouse secondary antibody conjugated with Cy3 for 
1h at room temperature and counter-stained with lectin for scoring the total 
microglial cell number. The percentage of BrdU positive cells was determined 
by randomly scoring 5 fields for each experimental and control groups in each 
independent experiment (n=3). The proliferation index is expressed as mean ± 
SD of the percentage of BrdU positive cells.  
2.2.10 Nitric Oxide (NO) Assay  
2.2.10.1 Principle 
NO is a neurotoxic molecule plays an important role in immune response, 
neurotransmission and apoptosis. It is synthesized from L-arginine by Nitric 
Oxide Synthase (NOS).  Griess assay is one of the simplest methods to detect 
NO concentration in biological samples. NO is first oxidized to nitrite (NO2-) 
and then to nitrate (NO3-) and the concentration of NO is determined by 
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quantifying these anions. In the first step of Griess reaction, nitrate is 
converted to nitrite by nitrate reductase. In the second step, Griess reagent is 
added to the samples, which converts nitrite to an azo compound with deep 
purple colour. The absorbance of the azo chromophore determines the total 
NO production (Knowles & Moncada 1994, Förstermann et al. 1991). 
 
2.2.10.2  Materials 
 Griess reagent system (Cat. No. 2577-01, US Biological, USA)  
 
2.2.10.3 Procedure 
Culture medium was collected from the culture of BV2 cells transfected with 
scrambled siRNA or Runx1t1 siRNA and treated with HDACi (n=3). The 
nitric oxide production in the culture medium was quantified colorimetrically 
using nitric oxide assay kit with a Griess reagent system. Equal volumes of 
culture medium and the Griess reagent (1% sulfanilamide, 0.1%N-(1-
naphthyl) ethylenediamine dihydrochloride and 2.5% H3PO4) were mixed and 
incubated at room temperature for 10min. E MAX precise microplate reader 
(Molecular Devices, USA) was used to record the absorbance at 540nm.  
 
2.2.11 Chromatin immunoprecipitation (ChIP) Assay 
2.2.11.1 Principle 
ChIP assay is a immunoprecipitation method used to detect protein-DNA 
interaction. This helps to determine the association of specific proteins such as 
transcription factors with specific genomic regions including gene promoters. 
This can be used to identify specific regions in the genome that are associated 
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with histone modifications. Briefly, in this assay, DNA and protein are cross-
linked and sonicated to shear DNA. The cross-linked DNA-protein is 
immunoprecipitated using appropriate antibodies to the protein of interest 
associated with the DNA fragment. The protein-DNA cross-link is reversed to 
free DNA and the purified DNA fragment is sequenced by direct high-




 Chromatin Immunoprecipitation Kit (EZ-ChIP) (Millipore, USA, 
Cat No: 17-371) 
 SDS lysis buﬀer (pH8.1, 1% SDS, 50mM Tris, 10mM EDTA, , 
Millipore, USA, Cat. No. 20-163). 
 Sonicator (Cat. No. UCD-200, Bioruptor, Diagenode Inc., USA) 
 Protein G agarose beads (Cat. No. 16-201D, Millipore, USA) 
 Rabbit anti-Runx1t1 antibody (Cat.No.sc-28693, Santa Cruz, USA) 
 Mouse anti-polymerase II antibody (Cat. No.05-623B, Millipore, 
Inc., USA) 
 IgG control antibody (Cat. No.sc-2027, Santa Cruz, USA) 
 Tris–EDTA buﬀer (Cat. No.20-157, Millipore, Inc., USA) 
 PCR purification kit (Cat. No. 28104, QIAGEN, USA) 
 Primers against LAT2 promoter region and GAPDH promoter 
region (See Table 2). 
 




Primer for LAT2 gene promoter was designed by selecting the genomic DNA 
sequence upstream of transcription start site (ATG) from NCBI and inputting 
this sequence in Primer 3 software. The primer specificity was confirmed by 
blasting the sequences in NCBI nucleotide BLAST.  
Chromatin immunoprecipitation was performed using Chromatin 




were cross-linked with 1% formaldehyde for 10min at room 
temperature and quenched with 0.125M glycine at room temperature for 5min. 
Then the cells were washed with ice-cold PBS containing protease inhibitors 
for two times, harvested and sonicated using SDS lysis buﬀer (50mM Tris, 
pH8.1, 10mM EDTA, 1% SDS). A sonicator was used to shear chromatin on 
high power for 3×10 cycles and the chromatin extracts were precleared with 
50% suspension of ChIP blocked protein G agarose for 1h and 
immunoprecipitated with 8μg of anti-Runx1t1 antibody, or anti-polymerase II 
antibody or IgG control antibody overnight, respectively at 4⁰C. Immune 
complexes were recovered and washed with with low and high salt buﬀer, 
LiCl immune complex buﬀer, and Tris–EDTA buﬀer. Elution buﬀer was used 
to elute the immunocomplex and the DNA-protein crosslink was reverted by 
incubating at 65⁰C overnight. The samples (10µg) were subjected to RNase A 
digestion for 37min at 37⁰C and proteinase K digestion for 2h at 37⁰C). The 
immunoprecipitated DNA was purified with PCR purification kit. Input DNA 
(genomic DNA, 1%) was also purified from the precleared chromatin. 
Quantitative RT-PCR was performed on an AB thermal cycler using the Fast 
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SYBR Green PCR master mix,  2µl of immunoprecipitated DNAs,  genomic 
DNAs and primers against LAT2 promoter region (Table 2) or GAPDH 
promoter region (Table 2) (n=3). 
 
2.2.12 Overexpression of dominant negative (DN) PPARɣ in BV2 
microglia 
2.2.12.1 Principle 
Traditional approaches for studying protein functions have several limitations. 
One of the alternative approaches is to engineer mutations in the protein of 
interest which inhibits or masks the function of concurrently expressed wild 
type protein. In dominant-negative PPARɣ mutant, its DNA binding domain 
was abolished by amino acid substitution which prevents its binding to PPARɣ 
response element (PPRE) (Woo et al. 2011). Overexpression of this DN 
PPARɣ mutant inhibits the expression of endogenous PPARɣ and thereby 
exhibits loss of PPARɣ function.  
 
2.2.12.2 Materials and methods 
 PPARɣ mutant (PPARɣC126A/E127A) (DN-PPARɣ) plasmid was 
kindly provided by Dr. Alan Prem Kumar (CSI, Singapore) (Woo et al. 
2011) 
 TOP10 E.coli cells (Invitrogen, USA, Cat. No. C4040-10) 
 Ampicillin (Sigma- Aldrich, USA, Cat. No.A0166) 
 Luria broth (LB) (Sigma- Aldrich, USA, Cat. No. L3022) 
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The highly competent E.coli cells transfected with (pCAMEX) plasmid with 
or without DN PPARɣ insert were scaled upto 50ml using ampicillin 
containing LB broth. The culture was incubated at 37°C in an orbital shaker 
overnight at 250rpm. In the next day, the plasmid was extracted using 
midiprep protocol according to the manufacturer’s instructions. The culture of 
transfected cells was harvested by centrifugation and the pellet was 
resuspended in resuspension buffer. Lysis buffer was added and the mixture 
was homogenized by inverting the tube and incubated for 5 min at room 
temperature. In the next step, the precipitation buffer was added to the culture 
and centrifuged for 10min at 12,000 rpm. The equilibrated column was loaded 
with the supernatant and allowed to flow down by gravity. In the next step, the 
plasmid DNA was eluted by adding elution buffer (5ml) and allowed to flow 
down by gravity. In the following step, the plasmid DNA was washed with 
isopropanol and 70% ethanol. After washing with ethanol, the plasmid was 
resuspended in 10ml TE buffer and stored at -20°C. 
For overexpression, the BV2 microglial cells (2x10
5
 cells) were seeded 
on to a 6 well plate (n=3). Transfection in microglial cells was performed 
according to the manufacturer’s instruction. Transfection complexes were 
prepared by mixing 2μl of Lipofectamine 2000 transfection agent and 4μg of 
plasmid DNA (pCAMEX with or without DN-PPARɣ insert) in 500ml 
OPTIMEM Serum-free Medium and incubated for 15min at room 
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temperature. The transfection mixture was then added on to the cells in the 6 
well plate, made up the total volume to 2.5ml with OPTIMEM and incubated 
for 48h in 6-well (2x10
5
 cells/well) or 24-well (4x10
4
 cells/well) plates. The 
cells were treated with LPS, Costunolide and Costunolide+LPS followed by 
48hrs of transfection. 
 
2.3 Statistical analysis 
 
Data used for statistical analysis were derived from three to four independent 
experiments and presented as means +/- standard deviation (SD). Statistical 
significance was evaluated by either the Student’s t-test or one-way ANOVA. 













































3.1 Runx1t1 (runt-related transcription factor 1; translocated 
to, 1) epigenetically regulates the proliferation and nitric 
oxide production of microglia 
 
3.1.1 Microarray Analysis showed that Runx1t1 is exclusively expressed 
in amoeboid microglia 
 
It is well established that microglia which are distributed abundantly in the 
corpus callosum of the brain, appear amoeboid in shape in the postnatal brain 
Fig. 1 A) and gradually transform into the ramified phenotype in the adult 
brain (Fig. 1 B). 
 
 
Fig. 1. A-B. Confocal images showing AMC in the corpus callosum (CC) of 
post-natal rat brain (A; green) and RMC with extended process in the CC of 









 A recent microarray study comparing global gene expression profiles of 
amoeboid  and ramified microglia showed that Runx1t1 was highly expressed 
in amoeboid microglial cells when compared to that in ramified microglia 
(Parakalan et al. 2012). In this microarray analysis, total RNA was extracted 
from the amoeboid and ramified microglial cells isolated from the corpus 
callosum of 5d and 4w old rat brain sections by laser-capture microdissection. 
Gene expression was analyzed according to GeneChip Operating Software 
(GCOS, Affymetrix, CA, USA) (Parakalan et al. 2012) and pathway analysis 
for genes that are differentially expressed in AMC and RMC was performed 
using Pathway Studio (Fig. 2). The dataset can be accessed using the GEO 
Series accession number GSE29885 at NCBIs Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/). 
Fig. 2. Pathway analysis showing genes that are differentially expressed in 
AMC and RMC [Adapted from (Parakalan et al. 2012)]  
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3.1.2 Temporal expression of Runx1t1 immunoreactivity in microglial 
cells of normal rat brain 
Immunofluorescence analysis by confocal microscopy showed Runx1t1 
immunoreactivity in OX42-positive amoeboid microglial cells (AMC) that 
were found in the corpus callosum of 1d, 3d and 5d-old rat pups (Fig. 3 A-I). 
The intensity of Runx1t1 expression in microglia appears to decline gradually 
from 7d onwards (Fig. 3 J-L). In rats aged 14d and 21d, Runx1t1 expression 







Fig. 3. A-R. Double immunofluorescent staining shows the co-localisation 
of Runx1t1 and OX42 in the microglia of postnatal rat brain. Confocal 
images showing the expression of Runx1t1 (B,E,H,K,N,Q; red) in OX42-
positive (A,D,G,J,M,P; green)  microglia (C,F,I,L,O,R; yellow) from the 
corpus callosum of 1, 3, 5,7, 14& 21days rat brains. Note that the expression 
of Runx1t1 (arrows) decreases with age and is hardly detectable in the 
microglia of 14d and 21d postnatal rat brain. Nuclei are stained with DAPI. 
Scale bar: 20μm. (n=3). 
 
The number of Runx1t1 immunoreactive microglia in the corpus callosum of 
1, 3, 5, 7, 14& 21days rat brains was enumerated. The quantitative analysis 
showed that the number of Runx1t1 immunoreactive microglia significantly 
decreased with age in normal rats. Runx1t1 immunoexpression was clearly 
evident in amoeboid microglial cells in the 1d, 3d and 5d old rat brain sections 
and its expression level was markedly reduced in ramified microglial cells in 
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Fig. 4. Quantitative analysis showing the percentage of Runx1t1 positive 
microglia in the corpus callosum. The number of Runx1t1 immunoreactive 
microglia decreases with age in normal rats. Significant differences between 
groups (1D vs14D, 1D vs 21D, 3D vs 21D, 5D vs 14D, 5D vs 21D) are 
indicated by * p<0.05, **p<0.01 (n=3). 
 
3.1.3 Runx1t1 expression is upregulated in activated microglia in vivo  
As microglial cells are known to respond to neuroinflammation and injury, we 
have examined if there is any change in expression of Runx1t1 in microglia 
exposed to LPS, which is an endotoxin causing inflammation in the brain. 
Runx1t1 immunoreactivity was found to be induced in activated microglia 
distributed in the corpus callosum of 5 day and 4 weeks old rats, 3h after 
injection of LPS (Fig. 5 D-F, J-L) when compared to the control cells (Fig. 5 
A-C, G-I). Nuclear translocation of Runx1t1 protein was also evident in some 




























































Fig. 5. Runx1t1 protein expression in LPS activated microglia. Confocal 
images showing the colocalization of Runx1t1 (B-E, H-K; red) and OX42 (A-
D, G-J; Green) in control (A-C, G-I) and LPS-treated (D-F, J-L) activated 
microglia from the corpus callosum of 5day and 4 week rat brain sections. 
Nuclear translocation of Runx1t1 is evident in LPS-treated activated microglia 
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For in vitro analysis, the optimal dose of LPS was determined from the 
viability of BV2 microglia after LPS treatment with doses of 0.1, 0.5 1, 3, 10 
μg/ml for 1h, 3h, 6h (Fig. 6). MTS assay was performed to determine the 
toxicity of LPS and the viability of BV2 microglial cells after treatment with 
various concentrations of LPS. The viability of cells treated with up to 1μg/ml 
concentration of LPS was near normal levels compared to untreated control 
cells. However, cell viability seemed to be reduced at 3μg/ml and 10μg/ml 
concentrations of LPS. 
 
Fig. 6. MTS assay shows the effect of various concentrations of LPS 
(0.1μg/ml-10μg/ml) on the viability of BV2 microglial cells. Treatment of 
BV2 microglial cells with different concentrations of LPS (0.1μg/ml-10μg/ml) 
for 1h, 3h and 6h revealed that LPS did not affect the cell viability up to 
1μg/ml concentration. Cell viability was decreased with further increase in the 
concentration of LPS. Significant differences between groups (Control vs LPS 









































3.1.4 Runx1t1 mRNA and protein expression levels are upregulated in 
LPS-activated primary microglial cells in vitro 
The mRNA and protein expression levels of Runx1t1 were detected in primary 
microglial cells in vitro. Runx1t1 mRNA expression was significantly 
upregulated in primary microglial cells exposed to LPS for 3h (Fig. 7 A-B). 
This was further confirmed by western blot analysis which showed that 
Runx1t1 protein expression was significantly increased in primary microglial 
cells exposed to LPS for 3h (Fig. 7 C-D). Based on these findings and findings 
from cytotoxicity assay, the time point (3h) and dosage (1μg/ml) of LPS 
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Fig. 7. A-D. mRNA and protein expression of Runx1t1 in LPS-activated 
primary microglia. A-B. qRT PCR shows that Runx1t1 mRNA expression is 
significantly upregualated in primary microglia 3h after LPS treatment. The 
data are normalized with the β-actin (B) and presented as mean ± S.E. C-D. 
Western blot analysis shows that there is a significant upregulation of Runx1t1 
protein expression in LPS-treated primary microglial cells when compared to 
control. Runx1t1 (70kDa) and β-actin (42kDa) immunoreactive bands are 
shown (C). Significant differences between the groups (Control vs LPS) are 
indicated by * p<0.05. (n=3). 
 
Immunofluorescence analysis also showed that Runx1t1 immunoreactivity 
was increased in primary culture microglial cells treated with LPS for 3h (Fig. 
8 D-F) when compared to control (Fig. 8 A-C). Nuclear translocation of 
Runx1t1 protein was evident in LPS-activated microglial cells (Fig. 8 E). 
 
 
Fig. 8. A-F. Runx1t1 protein expression in primary microglia. Confocal 
images showing the co-expression of Runx1t1 (B, E; Red) and OX42 (A,D; 
Green) in primary culture microglia (A-F) treated with LPS for 3h (D-F). 
Runx1t1 expression appears to be markedly increased after 3h of LPS 
treatment (E; arrows). Nuclear localization of Runx1t1 is evident in activated 
microglia (E; arrows). Nuclei are stained with DAPI. Scale bars: 50µm. (n=3). 
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3.1.5 Runx1t1 protein expression is upregulated in activated microglia 
in the brain injury model and neurodegenerative disease model 
Since microglia is activated in response to brain injury and neurodegeneration, 
we have analyzed Runx1t1 expression in microglia of the brain from TBI and 
AD rat models (Fig. 9 A-F, Fig. 10 A-F). Post-TBI which is focal and specific 
to the CA1 region of hippocampus, the microglia appeared to be activated in 
the CA1 region of hippocampus as they are spherical and amoeboid in shape. 
Runx1t1 protein expression (Fig. 9 D-F) was found to be induced in the 
activated microglia when compared with that of the sham operated control 
animals (Fig. 9 A-C).  
 
 
Fig. 9. A-F. Runx1t1 protein expression in the activated microglia of the 
brain from TBI rat models: Confocal images showing the colocalization of 
Runx1t1 (B, E; Red) and OX42 (A, D; Green) in activated microglia in the 
CA1 region of hippocampus from TBI rat models (A-F). Control sections were 
obtained from the sham-operated rat brains (A-C). Runx1t1 expression 
appears to be induced in activated microglial cells 24h post-TBI (B, E; arrows) 





We have also analyzed the expression of Runx1t1 in microglia of the brain 
from Alzheimer‘s disease (AD) rat model. In age-matched control rat brains, 
Runx1t1 expression was hardly detectable (Fig. 10 A-C) in the microglial 
cells, whereas in the brain of AD rat model, Runx1t1 expression was found to 
be induced in activated microglia (Fig. 10 D-F) in the hippocampal region.  
 
 
Fig. 10.A-F. Runx1t1 protein expression in the activated microglial cells 
of AD rat models: Confocal images showing the colocalization of Runx1t1 
(B, E; Red) and OX42 (A, D; Green) in activated microglia in the CA1 region 
of hippocampus from AD rats (A-F). Runx1t1 expression appears to be 
induced in activated microglial cells in the hippocampus of AD rat (D-F) when 
compared to control sections (A-C). Nuclei are stained with DAPI. Scale bars: 
50µm.  
3.1.6 siRNA-mediated knockdown of Runx1t1 suppresses microglial 
proliferation and expression of cell-cycle related genes in BV2 
microglia  
We have used siRNA-mediated loss of function approach to understand the 




siRNA which was designed to knockdown the expression of endogenous 
Runx1t1. The transfection was considered to be efficient since the Runx1t1 
mRNA expression level was found to be decreased by 90% in transfected cells  
(Fig. 11). 
 
Fig. 11. Transfection efficiency of Runx1t1 siRNA in BV2 microglial cells: 
qRT-PCR analysis shows that Runx1t1 mRNA expression is significantly 
down-regulated in Runx1t1 siRNA transfected cells when compared with 
scrambled siRNA transfected cells. Two siRNA constructs were used and the 
construct 2 was considered effective as it showed 90% downregulation of the 
target gene.  Significant differences between scrambled siRNA vs Runx1t1 
siRNA is indicated by **p<0.01, (n=3). 
 
The cells appeared viable after siRNA transfection and the transfection 
efficiency was further confirmed by transfecting the cells with CY3-
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Fig. 12. Transfection efficiency and cell viability after Runx1t1 siRNA 
transfection in BV2 microglia: A-C. Fluorescent microscopy images 
showing a high transfection efficiency of CY3–conjugated GAPDH siRNA  
(which serves as positive control) into BV2 microglia (A-C, Red; arrows).  
 
The siRNA–mediated knockdown efficiency was further confirmed by the 
immunofluorescence analysis of Runx1t1 in transfected BV2 microglia. This 
analysis showed the considerable decrease in Runx1t1 protein expression in 
BV2 microglial cells after siRNA knockdown of Runx1t1, when compared to 
that in cells transfected with scrambled siRNA (Fig. 13 A, B). The expression 
was hardly detectable in majority of those microglial cells.  
 
Fig. 13. Confocal images showing Runx1t1 protein expression in Runx1t1 
siRNA transfected BV2 microglial cells: Confocal images showing the 
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Runx1t1 expression in BV2 microglial cells transfected with scrambled 
siRNA (A) and Runx1t1 siRNA (B). Runx1t1 expression is hardly detectable 
in majority of the microglia 24h after Runx1t1 siRNA transfection (B). Nuclei 
are stained with DAPI. Scale bars: 50µm.  
 
Western blot analysis also showed a significant reduction in Runx1t1 protein 
expression in BV2 microglia after the knockdown of Runx1t1 with siRNA 
(Fig. 14 A, B).  
 
 
Fig. 14. Protein expression of Runx1t1 in Runx11t1 siRNA-transfected 
BV2 microglial cells: A-B. Western blot analysis showing a marked 
downregulation of Runx1t1 protein expression in Runx1t1 knockdown BV2 
microglial cells when compared to that transfected with scrambled siRNA. 
Runx1t1 (70kDa) and β-actin (42kDa) immunoreactive bands are shown (A). 
Significant differences between the two groups (scrambled siRNA vs Runx1t1 


































































3.1.7 BrdU incorporation assay revealed that knockdown of Runx1t1 
reduces microglial proliferation 
Microglial proliferation is associated with microglial activation in 
neuropathological conditions (Kreutzberg 1996). The proliferation index of 
BV2 microglia after Runx1t1 knockdown was determined by the BrdU 
incorporation assay. BrdU incorporation assay revealed that the knockdown of 
Runx1t1 significantly decreased the mitotic index of BV2 microglia cells (Fig. 
15 A-H, I). LPS treatment significantly increased the number of BrdU positive 
cells in the culture of BV2 microglia transfected with scrambled siRNA (Fig. 
15 E, F, I). However, the number of BrdU positive cells was found to be 
significantly decreased in Runx1t1 knockdown BV2 microglial cells treated 
with or without LPS  (Fig. 15 C,D, G-I) when compared to the culture 
containing scrambled siRNA-transfected BV2 microglia (Fig. 15 A,B, E,F, I) 
indicating the role of Runx1t1 on microglial proliferation. Quantitative 
analysis of the immunofluorescence also confirmed that the number of BrdU 
positive cells was significantly decreased in culture containing Runx1t1 
knockdown BV2 microglia when compared to scrambled siRNA treated 


















































































Fig. 15. A-H. Confocal images showing the BrdU immunostaining (Red) 
in lectin-positive (Green) BV2 microglia: The number of BrdU-positive 
microglial cells (transfected with scrambled siRNA) appears to be markedly 
increased in BV2 microglia culture treated with LPS (E, F: arrows), when 
compared to the culture containing control microglia cells transfected with 
scrambled siRNA (A, B). In contrast, the LPS-induced increase in number of 
BrdU positive microglial cells is not evident after siRNA-mediated Runx1t1 
knockdown (G, H: arrows), when compared to the culture containing 
microglia transfected with scrambled siRNA (C,D,E,F). Nuclei are stained 
with DAPI. Scale bars: 50µm.  
I. Quantitative analysis shows a significant decrease in number of BrdU 
immunoreactive BV2 microglia in activated microglia cultures transfected 
with Runx1t1siRNA for 24h. Significant differences between groups 
(scrambled siRNA vs Runx1t1 siRNA, scrambled siRNA +LPS vs Runx1t1 
siRNA+LPS) are indicated by * p<0.05, **p<0.01 (n=3). 
 
3.1.8 Runx1t1 knockdown reduces Cdk4 expression in BV2 microglia 
Since BrdU incorporation assay revealed that the Runx1t1 may regulate 
proliferation index of microglia, the expression of Cdk4, a cell cycle protein 
involved in microglial proliferation was studied after Runx1t1 knockdown. 
Western blot analysis showed that Cdk4 protein expression was upregulated in 
















































Runx1t1 was found to downregulate the Cdk4 protein expression significantly 
in BV2 microglial cells treated with or without LPS, when compared to the 
scrambled siRNA transfected microglial cells (Fig. 16 A-B). 
 
Fig. 16. Effect of Runx1t1 knockdown on the Cdk4 protein expression in 
LPS-activated BV2 microglia: A-B. Western blot analysis shows that Cdk4 
protein expression is upregulated in LPS-treated BV2 microglial cells (A-B). 
However, a significant downregulation of Cdk4 protein expression is detected 
in LPS-treated BV2 microglia after knockdown of Runx1t1 (A-B). The 
significant difference between the groups (scrambled siRNA vs scrambled 
siRNA +LPS, Runx1t1 siRNA vs Runx1t1 siRNA+LPS and scrambled siRNA 
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3.1.9 HDACi inhibits microglial proliferation, mimicking the effect of 
Runx1t1 knockdown in microglia 
Since Runx1t1 has been shown to recruit histone deacetylases (HDAC) for 
transcriptional repression (Gelmetti et al. 1998, Davis et al. 2003), effect of 
HDAC inhibition on microglial proliferation was examined. Treatment with 
HDACi (sodium butyrate, 5mM) showed a similar effect of Runx1t1 
knockdown on microglial proliferation. BrdU incorporation assay showed a 
significant decrease in number of BrdU
 
positive microglial cells following 
treatment of HDACi with or without LPS in comparison to that of control as 




















































Fig. 17. A-H. Confocal images showing inhibition of BrdU incorporation 
in BV2 microglial cells treated with HDAC inhibitor: Microglial cells are 
immunostained with BrdU [(A,C,E,G); red] and counterstained with lectin and 
DAPI (B,D, F, H). The number of BrdU positive cells (E-H);arrows) 
decreased at 12h after HDAC inhibitor treatment in BV2 microglia culture 
treated with or without LPS.  Scale bars: 50µm.  
I. Quantitative analysis shows a significant decrease in number of BrdU 
immunoreactive cells in BV2 microglial cells treated with HDACi for 12h. 
Significant differences between groups (control vs HDACi, Control vs 
HDACi+LPS) are indicated by **p<0.01 (n=3). 
 
 
3.1.10 Runx1t1 knockdown and HDACi treatment induces histone 
acetylation in microglia 
Since HDACi treatment has been reported to increase the histone acetylation 
(Zhou et al. 2011, Abdanipour et al. 2012), the global acetylation status of 
BV2 microglia was examined after HDACi treatment and Runx1t1 
knockdown using anti-acetyl-histone H3 (K9/14) antibody. A marked increase 
in acetylation was observed in the nuclei of microglia after HDACi treatment 

















































siRNA-mediated knockdown of Runx1t1 also increased the acetylation 
markedly in microglia treated with LPS (Fig. 18 K-L) when compared to 
























Fig. 18. A-L Confocal images showing acetyl-histone H3 (K9/14) 
immunostaining (Red) in BV2 microglial cells which are counterstained 
with lectin (Green) and DAPI (Blue). HDACi treatment increased acetyl-
histone H3 staining in microglial cells(C, D) when compared to control 
microglia (A, B). Further, knockdown of Runx1t1 markedly increased acetyl-
histone H3 in microglial cells treated with or without LPS (I-L) when 

































































3.1.11 HDACi treatment downregulates the expression level of Cdk4 as in 
Runx1t1 knockdown microglial cells 
It is clear that the effect of HDACi mimics the Runx1t1 knockdown on 
microglial proliferation. In view of this, the effect of HDACi on the mRNA 
and protein expression levels of Cdk4 in control and LPS-treated microglia 
was analyzed. RT-PCR analysis showed that the mRNA expression of Cdk4 
was significantly downregulated in HDACi and HDACi+LPS treated BV2 
microglial cells when compared to control (Fig. 19). However, LPS treatment 




Fig. 19. Cdk4 mRNA expression in BV2 microglia treated with HDACi: 
qRT-PCR analysis shows that Cdk4 mRNA expression is significantly 
upregulated in LPS-treated BV2 microglia and however, downregulated in 
microglia treated with HDACi. Significant differences between groups 














































This was further confirmed by western blot analysis which showed a 
significant reduction of Cdk4 protein expression in HADCi and HDACi+LPS 
treated BV2 microglia when compared to control and LPS treated microglial 
cells (Fig. 20 A, B). 
 
 
Fig. 20. Cdk4 protein expression in BV2 microglia treated with HDACi: 
A-B, Western blot analysis showed the downregulation of Cdk4 (34kDa) 
expression in BV2 microglia treated with HDACi alone or HDACi+LPS. The 
data are normalized with β-actin (42kDa) immunoreactivity (A). Significant 
differences between groups (control vs LPS, LPS vs HDACi and LPS vs 
HDACi +LPS) are indicated by * p<0.05, (n=3). 
 
3.1.12 Expression of LAT2 in microglia 
It has been shown that the Runx1t1 targets and represses the expression of 
LAT2, L-aminoacid transporter-2 (cationic amino acid transporter, y+ 
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expression was analyzed in microglia which produce NO excessively when 
activated (Chao et al. 1992). Immunofluorescence analysis showed that LAT2 
was expressed in OX42-positive AMC found in the corpus callosum of 5-7 d 




Fig. 21. LAT2 expression in AMC and BV2 microglia: A-F. Confocal 
images showing the expression of LAT2 (B,E; red) in OX42-positive (A,D; 
green) microglia (C,F; yellow) from the corpus callosum of  5 & 7days rat 
brains. G-I. Confocal images show the expression of LAT2 (H, I; red) in BV2 
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3.1.13 Knockdown of Runx1t1 or HDACi treatment upregulates LAT2 
which reduces NO production in BV2 microglial cells. 
LAT2 is an amino acid transporter mediating the entry of arginine to CNS. It 
has been shown to deplete the availability of arginine to iNOS enzyme leading 
to reduction in the NO production (Zielinska et al. 2011). LAT2 protein 
expression was analyzed in the BV2 microglial cells after Runx1t1 
knockdown. LAT2 protein expression was significantly decreased in LPS 
activated BV2 microglial cells transfected with scrambled siRNA when 
compared to non-activated control microglial cells transfected with scrambled 
siRNA. However, Runx1t1 knockdown significantly upregulated the protein 
expression of LAT2 in BV2 microglial cells treated with or without LPS, 
when compared to scrambled siRNA transfected microglial cells (Fig. 22.A, 
B).








































































Runx1t1 siRNA: A-B. Western blot analysis shows that expression level of 
LAT2 protein (58kDa) is significantly downregulated in microglia treated with 
LPS, when compared to that transfected with scrambled siRNA. On the other 
hand, knockdown of Runx1t1 significantly upregulated the LAT2 protein 
expression in LPS-treated BV2 microglial cells. The data were normalized 
with β-actin (42kDa). 
 
The effect of HDACi treatment on protein expression level of LAT2 was also 
examined in BV2 microglia to check whether HDACi treatment mimics the 
Runx1t1 knockdown effect on LAT2 expression in BV2 microglial cells. 
Western blot analysis showed a significant downnregulation of LAT2 protein 
expression in LPS activated microglial cells. However, there was a significant 
upregulation of LAT2 protein expression in HDACi+LPS-treated BV2 
microglial cells when compared to control (Fig. 23 A, B), indicating that 






Fig. 23. Expression of LAT2 protein in BV2 microglia treated with 
HDACi: A,B. Western blot analysis shows a significant upregulation of LAT2 
protein expression in LPS-treated BV2 microglial cells when exposed to 
HDACi. LAT2 expression is reduced in LPS-activated microglia. Significant 
differences between groups (scrambled siRNA vs scrambled siRNA +LPS, 
scrambled siRNA vs Runx1t1 siRNA, scrambled siRNA +LPS vs Runx1t1 
siRNA+LPS, control vs LPS, LPS vs HDACi+LPS, HDACi vs HDACi+LPS) 
are indicated by* p<0.05, **p<0.01 (n=3). 
 
It has been previously shown that enhanced expression of LAT2 contributes to 
a decreased production of NO (Zielinska et al. 2011). To address this in 
activated microglia, NO production was analyzed in activated BV2 microglia 
after knockdown of Runx1t1 or HDACi treatment (Fig. 24 A, B).  NO assay 
analysis revealed that knockdown of Runx1t1 or HDACi treatment decreased 
the level of nitrite significantly, possibly as a consequence of induction of 
LAT2 in BV2 microglial cells (Fig. 24 A, B). 
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Fig. 24. NO productionin BV2 microglia transfected with Runx1t1 siRNA 
or treated with HDACi: A, B. Nitric oxide (NO) assay analysis indicates that 
nitrite level is significantly increased in LPS-treated BV2 microglial cells and 
is brought down to near base level either by siRNA-mediated knockdown of 
Runx1t1 (A) or by HDACi treatment (B). Significant differences between 
groups (scrambled siRNAvs scrambled siRNA +LPS, scrambled siRNA +LPS 
vs Runx1t1 siRNA+LPS, control vs LPS, control vs HDACi+LPS, LPS vs 














































































3.1.14 ChIP assay reveals that Runx1t1 binds to LAT2 gene promoter 
and HDACi enhances this binding in activated BV2 microglia 
ChIP assay was carried out to investigate the interaction of Runx1t1 protein 
with LAT2 gene promoter using primers specific to LAT2 (Fig. 25 A-C). ChIP 
analysis revealed that Runx1t1 binds to LAT2 gene promoter and this binding 
was significantly increased in LPS-activated microglial cells when compared 
to control microglial cells (Fig. 25 A). Remarkably, HDACi treatment also 
increased the binding of Runx1t1 to the LAT2 promoter in LPS-activated 
microglial cells, compared to that of control (Fig. 25 A). Rabbit IgG was used 
as the negative control to exclude non-specific binding in all the experiments. 
Polymerase II binding at the GAPDH promoter was used as the positive 







Fig. 25. ChIP assay analysis showing the binding of Runx1t1 to LAT2 
gene promoter: A-C. ChIP analysis revealed that binding of Runx1t1 to the 
promoter region of LAT2 is significantly increased in LPS-activated 
microglial cells treated with or without HDACi, when compared to control 
microglial cells (A, C). For all experiments, rabbit IgG was used as the 
negative control to exclude non-specific binding. Polymerase II binding at the 
GAPDH promoter was used as the positive control (B, C). Significant 
differences between groups (control vs LPS, control vs HDACi+LPS, LPS vs 



























































































3.2 Costunolide binds with PPARγ and inhibits microglia-
mediated neuroinflammation post traumatic brain injury  
 
3.2.1 Microglial cells are activated in the CA1 region of hippocampus 
post-TBI 
Traumatic brain injury (TBI) rat models were created using the Lateral Fluid 
Percussion Injury (LFPI) method. Microglial cells of the CA1 region of 
hippocampus in the ipsilateral side of the injury were found to be activated. 
The amoeboid microglial cells appeared amoeboid in shape (Fig. 26 B,D,F) 
when compared to the microglial cells in the contralateral side (Fig. 26 A,C,E) 





Fig. 26. Confocal images showing OX42 stained amoeboid microglial cells 
in the CA1 region of hippocampus post-TBI: TBI activates microglial cells 
in the CA1 region of the hippocampus (B, D, F; green). The OX42 stained 
microglial cells in the ipsilateral side of the injury appears activated and 
amoeboid in shape (B, D, F; green, arrows) when compared to the microglial 
cells in the contralateral side of the injury which appears ramified in 
morphology (A,C,E; green, arrows). Scale bars: 500µm (A,B), 200 µm (C,D) 
and 50 µm (E,F)  
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An increased number of activated microglial cells were seen in the CA1 region 
of hippocampus (Fig. 27 D) when compared to that in the corpus callosum 
(CC) (Fig. 27 B) as FPI is specific to hippocampal region. In sham operated 
control animals microglial cells appeared ramified in shape in both CC and 
hippocampus (Fig. 27 A,C, Green). 
 
 
Fig. 27. Confocal images showing more number of activated microglial 
cells in CA1 region of hippocampus: The number of OX42 positive 
activated microglial cells was seen more in the CA1 region of hippocampus 
(D, green, arrows) when compared to corpus callosum (CC) (B, green, arrows) 
post-TBI. In sham operated control animals, microglial cells appeared 
ramified in shape in both CC and hippocampus (A,C, green, arrows). Scale 
bars: 50 µm. 
  











3.2.2 Costunolide inhibits NFκB nuclear translocation in activated 
microglia post-TBI. 
The transcription factor NFκB, a master regulator of inflammation, plays a 
pivotal role in neurodegeneration associated with CNS inflammation 
(Camandola & Mattson 2007). Our group has previously shown that 
costunolide modulates BV2 microglial activation by downregulating the 
expression of pro-inflammatory cytokine through the attenuation of NFκB 
translocation and expression (Rayan et al. 2011). Considering these finding, 
the expression of NFκB in activated microglia post-TBI was examined (Fig. 
28 A-F, G). Immunofluorescence analysis showed the nuclear translocation of 
NFκB in activated microglia post-TBI (Fig. 28 B, E). However, costunolide 
treatment (24h) inhibited the NFκB nuclear translocation in activated 
microglia post-TBI (Fig. 28 C,F,G). NFκB immunoreactivity was hardly 
detectable in sham operated control microglial cells (Fig. 28 A,D) 
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Fig. 28. NFκB nuclear translocation in activated microglia post-TBI:  
A-F. Confocal images showing the expression of NFκB (A-C; red) in OX42-
positive (D-F; green) microglia (D-F; yellow) from the CA1 region of 
hippocampus of control, TBI and TBI+costunolide (20mg/kg, i.p, 24h) treated 
rat models. NFκB is translocated to the nucleus of activated microglia post-
TBI (B, E). However, costunolide treatment inhibits the nuclear translocation 
of NFκB in activated microglial cells of the TBI rat brain (C, F). Nuclei are 
stained with DAPI. Scale bars: 20μm. 
G. Quantitative analysis shows that costunolide treatment significantly 
reduced the number of activated microglia showing NFκB nuclear 
translocation post-TBI. Significant differences between groups (control vs 
TBI, Control vs TBI+Costunolide, TBI vs TBI+Costunolide) are indicated by 
*p<0.05, **p<0.01 (n=3) 
 
3.2.3   Costunolide reduces TNFα expression in activated microglia post-
TBI. 
It has been well established that elevated NFκB activity regulates the 
microglial TNFα expression (Rayan et al. 2011, Liu et al. 2011). In this study, 
the effect of costunolide on the dynamic expression of TNFα in activated 
microglia found in the CA1 region of hippocampus post-TBI was investigated 
using immunofluorescence analysis (Fig. 29 A-I, J). Being a major 























































activated microglia post-TBI (Fig. 29 D-F) when compared with the control 
group (Fig. 29 A-C). Interestingly, costunolide treatment substantially reduced 
the TNFα immunoreactivity in post-TBI microglia (Fig. 29 H,I, J). These 
results suggest that costunolide attenuates the upregulation of NFкB activity 


































Fig. 29. TNFα protein expression in activated microglia post-TBI and 
costunolide treatment: A-I. Confocal images showing the colocalisation of 
TNFα (B,E,H; green) in OX42-positive (A,D,G; red) microglia (D-F; yellow) 
from the CA1 region of hippocampus of control, TBI and TBI+costunolide 
(20mg/kg, i.p, 24h) treated rat models. TNFα immunoexpression appears to be 
induced in activated microglia cells 24h post-TBI (D-F; arrows) when 
compared with control (A- C; arrows). However, TNFα immunoexpression is 
markedly reduced in activated microglial cells treated with costunolide for 24h 
post-TBI (G-I). Nuclei are stained with DAPI. Scale bars: 20μm. 
J. Quantitative analysis shows that costunolide treatment significantly reduced 
the number of TNFα immunoreactive microglia post-TBI. Significant 
differences between groups (control vs TBI, TBI vs TBI+costunolide) are 
indicated by, **p<0.01, ***p<0.001 (n=3) 
  
3.2.4 Costunolide induces MKP1 expression in activated microglia post-
TBI 
Mitogen-Activated Protein Kinase Phosphatase-1 (MKP1), is a negative 
regulator of MAP kinase signaling pathway which is a major inflammatory 
pathway in the CNS (Eljaschewitsch et al. 2006, Huo et al. 2011). MKP1 













































dependent transcription of pro-inflammatory cytokines, thus contributing to 
neuroprotection (Rayan et al. 2011, Wancket et al. 2012). In the current study, 
treatment with costunolide promoted the expression of MKP1 in activated 
microglia found in the CA1 region of hippocampus post-TBI (Fig. 30 A-F, G). 
MKP1 expression was evident in activated microglia post-TBI (Fig. 30 B, E). 
Costunolide treatment further enhanced the MKP1 expression as evidenced by 
the increased number of MKP1 positive microglial cells when compared to 
activated microglia post-TBI (Fig. 30 C,F, G). This suggests that the anti-
inflammatory effect of costunolide on activated microglia might be mediated 
through increased MKP1 expression. 
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Fig. 30. Effects of costunolide treatment on MKP1 protein expression in 
activated microglial cells post-TBI: A-F. Confocal images showing the 
colocalisation of MKP1 (A-C; red) in OX42-positive (D-F; green) microglia 
(D-F; yellow) from the CA1 region of hippocampus of control, TBI and 
TBI+costunolide (20mg/kg, i.p, 24h) treated rat models. MKP1 
immunoexpression appears to be induced in activated microglia cells 24h post-
TBI (B, E; arrows) when compared with control (A, D; arrows). Further, 
MKP1 immunoexpression is markedly induced in activated microglial cells 
treated with costunolide for 24h post-TBI (C, F, arrows). Nuclei are stained 
with DAPI. Scale bars: 50μm. 
G. Quantitative analysis shows that costunolide treatment significantly 
increased the number of MKP1 positive microglia in the CA1 region of 
hippocampus post-TBI. Significant differences between groups (control vs 
TBI, control vs TBI+Costunolide, TBI vs TBI+Costunolide) are indicated by, 
**p<0.01, ***p<0.001 (n=3) 
 
3.2.5 Costunolide inhibits SphK1 expression in activated microglia post-
TBI  
Another important proinflammatory mediator that controls neuroinflammation 
is sphingosine kinase 1 (SphK1). SphK1 binds with its receptors in microglia 
and  increases the expression and production of proinflammatory cytokines 









































2011). We have previously shown that SphK1 mediates the production of 
TNFα and IL-1β in LPS activated microglial cells in vivo (Lin et al. 2011). In 
this study, effect of costunolide treatment on the expression profile of SphK1 
has been analyzed in activated microglia found in the CA1 region of 
hippocampus post-TBI (Fig. 31 A-F, G, H). SphK1 immunoreactivity was 
increased in activated microglial cells following TBI (Fig. 31 B, E) in 
comparison to the microglial cells in the sham operated control (Fig. 31 A, D). 
Remarkably, costunolide treatment inhibited the upregulation of SphK1 in 
activated microglia post-TBI (Fig. 31 C,F). This was further confirmed by 
western blot analysis using protein samples extracted from the CA1 region of 
hippocampus, which is the site of accumulation of activated microglia post-
TBI (Fig. 31 G,H). Reduced expression level of SphK1 protein was found in 
the CA1 region of hippocampus upon costunolide treatment (Fig. 31 G,H). 
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Fig. 31. Effect of costunolide treatment on SphK1 protein expression in 
activated microglia post-TBI: A-F. Confocal images showing the 
colocalisation of SphK1 (A-C; red) in OX42-positive (D-F; green) microglia 
(D-F; yellow) from the CA1 region of hippocampus of control, TBI and 
TBI+costunolide (20mg/kg, i.p, 24h) treated rat models. SphK1 
immunoexpression appears to be upregulated in activated microglia cells 24h 
post-TBI (B,E; arrows) when compared with control (A,D; arrows). However, 
SphK1 immunoexpression is markedly reduced in activated microglial cells 
treated with costunolide for 24h post-TBI (C,F). Nuclei are stained with DAPI. 
Scale bars: 50μm.  
G-H. Western blot analysis shows that SphK1 protein expression is 
significantly upregulated in activated microglia cells post-TBI (G,H). 
However, costunolide treatment significantly downregulated the SphK1 
protein expression in activated microglial cells 24h post-TBI (G,H). The 
significant difference between the groups (control vs TBI, control vs 
TBI+Costunolide) are indicated by * p<0.05, (n=6). 
 
 
3.2.6 Costunolide reduces Runx1t1 expression in activated microglia 
post-TBI  
Further, the effect of costunolide on the expression of Runx1t1 was examined 




















































TBI. We have shown that Runx1t1 is a novel a transcription factor expressed 
in AMC and activated microglial cells and is involved in regulating microglial 
proliferation and activation. Further, Runx1t1 expression was analyzed in 
activated microglial cells treated with costunolide post-TBI (Fig. 32 A-F). It 
was observed that Runx1t1 expression was induced in activated microglia 
cells post-TBI (Fig. 32 B,E) but markedly reduced after costunolide treatment 
to activated microglial cells post-TBI (Fig. 32 C,F) 
 
Fig. 32. Effect of costunolide treatment on Runx1t1 expression in 
activated microglia post-TBI: A-F. Confocal images showing the 
colocalisation of Runx1t1 (A-C; red) in OX42-positive (D-F; green) microglia 
(D-F; yellow) from the CA1 region of hippocampus of control, TBI and 
TBI+costunolide (20mg/kg, i.p, 24h) treated rat models. Runx1t1 
immunoexpression appears to be induced in activated microglia cells 24h post-
TBI (B,E; arrows) when compared with control (A,D; arrows). However, 
Runx1t1 immunoexpression is markedly reduced in activated microglial cells 
treated with costunolide for 24h post-TBI (C,F). Nuclei are stained with DAPI. 
Scale bars: 50μm.  
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3.2.7 Costunolide reduces Runx1t1 expression in BV2 microglial cells in 
vitro 
Effect of costunolide on the mRNA expression of Runx1t1 was analyzed in 
BV2 microglial cells by RT-PCR. The results showed that Runx1t1 mRNA 
expression was induced in activated microglial cells after LPS treatment (Fig. 
33). However, pre-tretament with costunolide for 30min significantly reduced 
the expression of Runx1t1 in activated BV2 microglial cells (Fig. 33). 
 
Fig. 33. Effect of costunolide treatment on Runx1t1 expression in 
activated BV2 microglia: RT-PCR analysis shows that Runx1t1 mRNA 
expression is significantly upregulated in activated BV2 microglia cells after 
LPS treatment. However, pre-treatment with costunolide for 30min 
significantly downregulated Runx1t1 mRNA expression in LPS-activated 
BV2 microglial cells. The significant difference between the groups (control 
vs LPS, LPS vs Costunolide+ LPS) are indicated by ** p<0.01,* p<0.05, 
(n=3). 
3.2.8 PPARγ expression is induced upon costunolide treatment to 
activated microglia 
In silico analysis predicted that costunolide exerts its effect on activated 
microglia by binding to PPARγ receptor. In view of this finding, the in vivo 














































Immunofluorescence analysis showed that PPARγ was expressed in the 
cytoplasm and nucleus of amoeboid microglial cells (Fig. 34 A-C) in the 
corpus callosum of post-natal rat brain. However, the nuclear expression of 
PPARγ was reduced in activated microglial cells by LPS in the post-natal rat 
brain (Fig. 34 D-F).  
 
Fig. 34. PPARγ expression in microglia in vivo: A-F. Confocal images 
showing the colocalization of PPARγ (B,E; red) and OX42 (A,D; green) in 
control (A-C) and LPS-treated (D-F) activated microglia from the corpus 
callosum of 5 day old rat brain. PPARγ is expressed in both cytoplasm and 
nucleus of microglial cells in the control (B; arrows). However, PPARγ 
nuclear expression is reduced in LPS-activated microglial cells (E; arrows). 
Nuclei are stained with DAPI. Scale bars: 20µm 
 
3.2.9 Costunolide induces PPARγ expression in activated microglia post-
TBI 
The effect of costunolide on PPARγ expression was studied to confirm 
costunolide-PPARγ interaction in vivo.  PPARγ expression was evident in 
ramified microglial cells found in the CA1 region of hippocampus of the adult 



























brain (Fig. 35 A-C). However, PPARγ expression was reduced in activated 
microglia post-TBI (Fig. 35 D-F) Interestingly, costunolide treatment in vivo 
enhanced PPARγ expression in the nucleus of activated microglia post-TBI 
(Fig. 35 G-I) 
 
Fig. 35. Effects of costunolide treatment on PPARγ protein expression in 
activated microglia post-TBI: A-I. Confocal images showing the 
colocalisation of PPARγ (B,E,H; red) in OX42-positive (A,D,G; green) 
microglia (C,F.I; yellow) from the CA1 region of hippocampus of control, TBI 
and TBI+costunolide (20mg/kg, i.p, 24h) treated rat models. PPARγ 
expression in the nucleus appears to be reduced in activated microglia cells 
24h post-TBI (E,F; arrows) when compared with control (B,C; arrows). 
However, PPARγ nuclear expression is markedly induced in activated 
microglial cells treated with costunolide for 24h post-TBI (H,I). Nuclei are 
stained with DAPI. Scale bars: 20μm. 
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3.2.10 Costunolide induces PPARγ expression in activated microglial cells 
in vitro 
In vitro analysis using BV2 microglial cells showed that PPARγ nuclear 
expression was downregulated in activated microglial cells by LPS treatment 
(Fig. 36 D-F, M) compared to control cells (Fig. 36 A-C). On the other hand, 
pre-treatment with costunolide to LPS activated microglial cells induced 
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Fig. 36. PPARγ expression in BV2 microglia in vitro: A-L. Confocal images 
showing the colocalisation of PPARγ (B,E,H,K; red) in OX42 positive 
(A,D,G,H; green) BV2 microglia (C,F,I,L; yellow) treated with LPS, 
costunolide, and costunolide+LPS for 6h. Note the reduced nuclear expression 
of PPARγ after 6h of LPS treatment (E; arrows). Costunolide treatment 30min 
prior to LPS markedly induces PPARγ nuclear expression (K; arrows). Nuclei 
are stained with DAPI. Scale bars: 20µm. 
M. Quantitative analysis shows that costunolide treatment significantly 
induced the number of LPS activated BV2 microglial cells showing PPARγ 
nuclear expression. Significant differences between group (LPS vs 
Costunolide+LPS) is indicated by, **p<0.01, (n=3) 
 
 
3.2.11 Overexpression of Dominant Negative (DN) PPARγ masks 
endogenous PPARγ activity and induces NFκB signaling in 
activated microglia 
PPARγ exerts its anti-inflammatory effect by binding to specific DNA sites 
(PPAR responsive elements) on the promoters of proinflammatory genes for 
transcriptional repression. Dominant negative PPARγ (DN-PPARγ) is a 























































DNA binding and transcriptional activity, but can translocate to the 
nucleus, and mask the endogenous wild-type PPARγ expression. Loss of 
function studies with DN-PPARγ was performed to understand the role of 
PPARγ on activated microglia (Fig. 37 A-H, I). In DN-PPARγ transfected 
BV2 microglial cells, translocation of the PPARγ protein expression was 
found in both control and treatment groups (LPS, costunolide and 
costunolide+LPS) (Fig. 37 E-H, I). However, in empty vector (EV) treated 
BV2 microglial cells, the endogenous PPARγ expression was upregulated and 
translocated to nuclei only in response to costunolide treatment (Fig. 37 C,D, 
I). This clearly reveals that costunolide activates PPARγ expression and its 
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Fig. 37. Overexpression of Dominant Negative (DN) PPARγ in BV2 
microglia: A-H. Confocal images showing DN-PPARγ overexpression in 
BV2 microglial cells treated with LPS, costunolide and costunolide+LPS (E-
H). PPARγ protein expression is upregulated and translocated to the nuclei in 
both control and treatment groups (LPS, costunolide, costunolide+LPS) of 
BV2 microglia which are transfected with DN-PPARγ (E-H). However, in 
empty vector (EV)-treated BV2 microglial cells which serves as control (A-
D), PPARγ expression is upregulated and translocated to nuclei only in 
costunolide and costunolide+LPS treated BV2 microglial cells (C,D). Nuclei 
are stained with DAPI. Scale bars: 50µm 
I. Quantitative analysis shows that in empty vector (EV) treated BV2 
microglial cells (which serves as control), the endogenous PPARγ expression 
is significantly upregulated only in costunolide and costunolide+LPS 
treatment groups. On the other hand, in DN-PPARγ overexpressed BV2 
microglial cells, the mutant DN-PPARγ expression is upregulated and 
translocated to the nulcei in both control and treatment groups (LPS, 
Costunolide, Costunolide+LPS). Significant differences between groups (EV 



























































NFκB nuclear translocation was studied in DN-PPARγ overexpressed BV2 
microglial cells to understand if the inhibition of NFκB translocation upon 
costunolide treatment was PPARγ-mediated (Fig. 38 A-F, G). 
Immunofluorescence analysis indicated that NFκB was translocated to the 
nucleus upon LPS treatment in activated microglia (Fig. 38 B,E). Costunolide 
inhibited NFκB nuclear translocation in empty vector treated activated 
microglia which serves as control (Fig. 38 C). However, costunolide did not 
inhibit NFκB nuclear translocation in DN-PPARγ overexpressed activated 
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Fig. 38. Overexpression of DN PPARγ on NFκB expression in microglia: 
A-F. Confocal images showing NFκB nuclear translocation in BV2 microglai 
transfected with DN PPARγ. NFκB is translocated to the nucleus of activated 
microglia cells transfected with both empty vector and DN PPARγ upon LPS 
treatment (B, E; red). Costunolide treatment 30min prior to LPS treatment in 
empty vector (EV) treated microglial cells (which serves as control) inhibits 
NFκB nuclear translocation (C). However, pretreatment of costunolide is 
unable to inhibit NFκB nuclear translocation in activated microglial cells 
transfected with DN PPARγ (F). Nuclei are stained with DAPI. Scale bars: 
50µm 
G. Quantitative analysis shows that costunolide treatment significantly 
reduced NFκB nuclear translocation in LPS-activated BV2 microglial cells 
treated with empty vector, but is unable to inhibit NFκB nuclear translocation 
in LPS-activated BV2 microglial cells transfected with DN-PPARγ. 
Significant differences between groups (EV Con vs EV LPS, EV LPS vs  EV 
Costunolide+LPS, DN Con vs DN LPS, DN Con vs DN Costunolide+LPS, 
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Microglial cells which are known to be involved in safeguarding the 
microenvironment of the CNS as the innate immune cells of the CNS, 
contribute to the development and maintenance of neuronal architecture and 
plasticity in the CNS (Hanisch & Kettenmann 2007). Microglia eliminate the 
damaged neurons in neuropathologies and prune the weaker synapses by 
phagocytosis for the normal functioning of the brain (Tremblay et al. 2011).  
It has been well established that the morphological features of 
microglia including amoeboid, ramified and reactive phenotype help in 
facilitating their functions during development and neuropathological 
conditions (Raivich 2005, Dheen et al. 2007). Recent reports show that the 
morphological transformation of microglia is functionally important as the 
microglia of different phenotypes have distinct molecular profiles (Parakalan 
et al. 2012) 
Microglial cells respond to any insult in the brain leading to their 
activation and rapid proliferation (Dheen et al. 2007). This activation is 
generally neuroprotective; however, chronic activation of microglial cells 
results in the excessive release of pro-inflammatory cytokines and NO which 
are neurotoxic to the surrounding brain parenchyma (Kreutzberg 1996).  
 Chronic activation of microglia in brain injuries induces 
neuroinflammation and neurodegeneration (Kumar & Loane 2012).  In 
addition, microglia have been linked to pathology and disease progression in 
various neurodegenerative disorders including, AD, PD, MS, Huntington’s 
disease, HIV dementia, Pick’s disease and stroke (Jordan et al. 1991, Tai et al. 
2007, Pavese et al. 2006, Paulus et al. 1993, Raghavendra Rao et al. 2000). 




activation is persistent in brain tumors and this activation supports the growth 
of tumor cells (Wei et al. 2013). 
  Many studies have attempted to understand the molecular mechanisms 
behind chronic microglial activation, since activated microglia have been 
shown to induce neurotoxicity in several neurodegenerative disorders 
including brain injury (Ramlackhansingh et al. 2011, Michelucci et al. 2009, 
Dheen et al. 2007, Kaur et al. 2007). Identification and manipulation of 
regulatory molecules such as transcription factors that control microglial 
activation and proliferation may help in attenuating microglia-mediated 
neuroinflammation. Additionally, anti-inflammatory drugs and herbal 
compounds hold promise for the treatment of microglial-mediated 
neuroinflammation as they possess inhibitory effects on activation and 
inflammatory response of microglia. The current study identified the key 
transcription factors such as Runx1t1, PPARγ that are involved in controlling 
microglial activation. Further this study suggested that cosunolide which has 
been shown to inhibit inflammatory response of microglia (Rayan et al. 2011) 








4.1 Runx1t1 (runt-related transcription factor 1; translocated 
to, 1) epigenetically regulates the proliferation and nitric 
oxide production of microglia 
 
Global gene expression analysis revealed that Runx1t1, a transcription factor 
involved in the proliferation and differentiation of hematopoietic stem cells 
(Okumura et al. 2007, Davis et al. 2003) is expressed in the AMC of post-natal 
rat pups, but not in the RMC of adult rats (Parakalan et al. 2012). In the 
present study, Runx1t1 was found to be induced in activated microglia in vitro 
and in mature brains of TBI and AD rat models. The induction of Runx1t1 in 
activated microglia is noteworthy due to the fact that this gene was expressed 
normally in AMC which are highly motile and prolific, but not in adult 
quiescent microglia, and it plays a putative role in cell proliferation 
(Kreutzberg 1996). The expression of Runx1t1 in the distinct microglial cell 
types such as AMC and reactive microglia in the developing brain and 
neuropathologies respectively, prompted us to speculate that Runx1t1 plays an 
important role in microglial proliferation and activation. 
 It has been well documented that microglial proliferation is one of the 
hallmarks in neuropathological conditions caused by infection, trauma or other 
neurological disorders (Paresce et al. 1996, Koshinaga et al. 2000, 
Ramlackhansingh et al. 2011). Microglial activation in response to infection 
and injury is followed by their migration to the site of infection or injury, their 
proliferation and phagocyotosis (Nakajima & Kohsaka 2001). It has been 




(Kato et al. 2003, Di Giovanni et al. 2005). Cell cycle progression is regulated 
by complex signaling pathways involving several molecules, including cyclin-
dependent kinases (Cdk) (Pines 1993, Sherr 1995). In the present study, 
knockdown of Runx1t1 in activated microglia downregulated the expression 
of cell-cycle related protein, Cdk4, and perturbed the proliferation of activated 
microglia indicating that Runx1t1 promotes microglial proliferation by 
regulating Cdk4 in neuropathological conditions. These results further confirm 
that Runx1t1 is implicated in microglial activation in neuropathological 
conditions. 
 Runx1t1 is known to recruit HDACs for transcriptional repression of 
target genes (Oakford et al. 2010, Gelmetti et al. 1998, Lutterbach et al. 1998, 
Davis et al. 2003, Wang et al. 1998). HDACs which catalyze histone 
deacetylation and chromatin condensation, are involved in controlling cell 
proliferation by regulating the cell cycle genes (Baumann et al. 2012, Mathew 
et al. 2010, Kouzarides 1999, Faraco et al. 2009). HDAC-mediated chromatin 
remodeling upregulates the expression of Cdk4 which forms complex with 
cyclin D1 and phosphorylates retinoblastoma protein (pRb) which in turn 
regulates the G1/S transition in the cell cycle (Ferreira et al. 2001, Mathew et 
al. 2010, Korenjak & Brehm 2005, Luo et al. 1998, Das et al. 2005). HDACi 
has been shown to induce deregulation of cell cycle genes, cyclin D1 and 
Cdk4 leading to hypophosphorylation of pRb (Baumann et al. 2012) which is 
growth suppressive state, thereby resulting in cell cycle arrest in multiple 
myeloma cells. Further in the adult neural stem cells, HDACi treatment 




together with histone acetylation at proximal promoter regions, leading to cell 
cycle arrest (Zhou et al. 2011). 
In this study, HDACi (sodium butyrate) was used to block the 
availability of HDACs to Runx1t1 for regulating the transcription of its target 
genes in microglia. This led to a decrease in Cdk4 expression and mitotic 
index in activated microglial cells, thereby confirming the interaction between 
Runx1t1 and HDAC in regulating the proliferation of activated microglia.  
This finding is interesting as histone acetylation has previously been 
shown to reduce the proinflammatory response of activated microglia 
(Soliman et al. 2012). Further, the present study also showed an increased 
histone acetylation in activated microglia following Runx1t1 knockdown as 
well as HDACi treatment. Together, these results strengthen the notion that 
Runx1t1 regulates the proliferation and proinflammatory response of activated 
microglia by interacting with HDACs.  
 In addition to increased proliferation, activated microglia secrete a 
number of proinflammatory cytokines and neurotoxic factors such as nitric 
oxide (NO) (Dheen et al. 2007). Recently, it has been reported that LAT2, a 
cationic amino acid transporter (y+ system) reduces NO production by 
depleting the availability of arginine to iNOS enzyme (Zielinska et al. 2011, 
Nicholson et al. 2001). In view of this, it has been speculated that the LAT2 
has a potential role in microglia-mediated neuroinflammation. Hence it was 
hypothesized that LAT2 is expressed in the microglia and regulates NO 
production by the activated microglia in neuropathological conditions. Since 
rapid proliferation and increased production of neurotoxic factors such as NO 




LAT2 and Runx1t1 in activated microglia was also among the prime focuses 
of this study.  
The present study demonstrated the LAT2 expression in microglia and 
revealed that knockdown of Runx1t1 and HDACi treatment upregulated LAT2 
gene expression, and suppressed NO production in activated microglia. It has 
also been demonstrated that LAT2 was repressed in activated microglial cells 
which showed upregulation of Runx1t1. However, the LAT2 expression was 
derepressed in activated microglia upon Runx1t1 knockdown and HDACi 
treatment. These results clearly show that the upregulation of Runx1t1 
represses LAT2 in activated microglia by recruiting HDAC for transcriptional 
repression. This was further confirmed by the promoter binding studies using 
ChIP assay which showed that the Runx1t1 protein binds to LAT2 gene 
promoter. Moreover, this binding was significantly increased in activated 
microglial cells cultured with or without HDACi, indicating that Runx1t1 
binds to LAT2 promoter in microglia irrespective of the presence of HDAC. 
However, Runx1t1 requires HDACs to transcriptionally repress LAT2, since 
LAT2 expression was upregulated in activated microglia after HDACi 
treatment. It appears that Runx1t1-induced transcriptional repression of LAT2 
in activated microglia was abolished by the HDACi treatment as reported 
earlier (Melnick et al. 2000). Overall, this study provides convincing evidence 
that Runx1t1 contributes to microglia-mediated neuroinflammation by 
inducing microglial proliferation and their secretion of neurotoxic factor when 
activated via its interaction with HDACs and LAT2. 
 In conclusion, it has been demonstrated that Runx1t1 regulates Cdk4 




proliferation. In addition, Runx1t1 interacts with HDACs for repressing the 
expression of its target gene, LAT2, which normally reduces the production of 
NO in microglia. The repression of LAT2 expression results in increased 
release of NO which may contribute to neurotoxicity. It is suggested that the 
knockdown of Runx1t1 or the inhibition of HDACs could revert the epigenetic 
changes in target genes such as LAT2, thereby inhibiting microglial activation 
in neuropathological conditions. 
 
4.2 Costunolide binds with PPARγ receptor in microglia and 
inhibits microglia-mediated neuroinflammation in 
Traumatic Brain Injury 
 
This part of the study mainly dealt with identifying the mechanism of action of 
costunolide on the inflammatory response of activated microglia post-TBI.  
TBI occurs due to a sudden trauma which leads to brain dysfunction (Finnie 
2013). Microglia, the sentinels providing the first line of defense in the CNS 
become activated in response to the tissue damage post-TBI 
(Ramlackhansingh et al. 2011, Ling & Wong 1993, Kaur et al. 2001). The 
microglia eliminate debris caused by neurodegeneration or infection via 
phagocytosis and mediate the neuroinflammatory response through the release 
of cytokine and chemokine (Kumar & Loane 2012, Ramlackhansingh et al. 
2011, Faden 2011, Koshinaga et al. 2000). Prolonged activation of microglia 
is detrimental as it leads to degeneration of the surrounding healthy neurons. 




microglial activation persist in the ipsilateral cortex and hippocampus for even 
months after the injury (Shitaka et al. 2011). Thus modulation of microglial 
activation post-TBI has been considered to be a critical step in treating 
neuroinflammation and subsequent neurodegeneration associated with TBI 
disorders (Jain 2011).  
 Costunolide, a herbal compound isolated from the root of Costus 
speciosus, is known to have a variety of biological effects, including anti-
inflammatory, anti-diabetic and anti-carcinogenic effects (Pandey et al. 2007, 
Rayan et al. 2011, Kang et al. 2004).  We have shown that costunolide inhibits 
the inflammatory response of LPS-activated BV2 microglia in vitro (Rayan et 
al. 2011). This study further demonstrates that costunolide modulates the 
inflammatory response of microglia in the lateral fluid percussion (LFP) brain 
injury model which recapitulates the hallmark pathobiological features of TBI 
(Morales et al. 2005, Kabadi et al. 2010). This TBI rat model produces 
ipsilateral cellular loss in the hippocampus, neuronal cell death and glial 
proliferation and activation (Morales et al. 2005, Dixon et al. 1987). 
 In response to TBI, microglia become activated, and migrate to the 
injury site as we observed in the CA1 region of the hippocampus. Further, 
these activated microglial cells exhibited upregulation of pro-inflammatory 
cytokines and NO in response to the trauma. Although microglial activation 
and their responses are necessary for tissue repair and normal neuronal cell 
functions, overactivation of microglia may contribute to neurotoxicity which 
could lead to neurodegeneration (Alvis-Miranda et al. 2013).  
 Recent in silico analysis via molecular docking mechanism by our 




(Rayan, N.A, PhD thesis, 2011). PPARs are ligand activated transcription 
factors belonging to the class of nuclear receptors. They control target gene 
expression in response to exogenous and endogenous ligands (Duez et al. 
2001, Braissant et al. 1996). PPARγ is one of the dominant PPAR isoforms 
expressed in microglia (Bernado et al., 2000; Burns et al., 2007) and is known 
to regulate inflammatory response in the brain (Kapadia et al. 2008, Schintu et 
al. 2009). PPARγ exhibits minimal transcriptional activity without ligand 
binding, but its expression increases when it is activated by ligands (Braissant 
et al. 1996). In silico docking results predicted a strong affinity binding 
between costunolide and PPARγ (Rayan, N.A, PhD thesis, 2011). This 
interaction was confirmed by in vivo analysis which showed that costunolide 
treatment induces PPARγ nuclear expression in activated microglia post-TBI. 
In vitro studies have also demonstrated that costunolide treatment 
induces PPARγ nuclear expression in LPS-activated BV2 microglia. Further, 
this PPARγ-costunolide interaction has been validated in vitro by 
overexpressing dominant negative (DN) PPARγ in BV2 microglia. 
Overexpression of DN- PPARγ inhibits the functional activity of endogenous 
PPARγ in BV2 microglia.  
Activation of endogenous PPARγ by its agonists inhibit NFκB nuclear 
translocation (Simone et al. 2011). In the present study, it was observed that 
DN-PPARγ overexpression (loss of function) did not inhibit nuclear 
translocation of NFκB in activated microglia followed by costunolide 
treatment, further indicating that costunolide delivers its anti-inflammatory 
effect in microglia through PPARγ receptor. This also provided experimental 




Activation of PPARγ has been shown to induce MKP1 expression and 
attenuate NFκB signaling pathway, resulting in anti-inflammatory effects 
(Gonon et al. 2007). In the present study, an increase in the number of MKP1 
positive microglial cells after costunolide treatment post TBI appears to be 
mediated by the interaction of costunolide and PPARγ.   
 There is mounting evidence that PPARγ ligands such as rosiglitazone, 
piogliatazone, trogliatazone and cigitazone exert anti-inflammatory effects 
through PPARγ activation in glial cells (Gonon et al. 2007, Youssef & Badr 
2013, Belvisi et al. 2006, Pan & Chen 2003). These PPARγ ligands have been 
shown to repress the expression of several inflammatory response genes 
including TNFα, IL-6, IL-1β and iNOS (Burston & Kendall 2013, Pan & Chen 
2003, Gonon et al. 2007). Costunolide mediates a similar repressive effect on 
the expression of various pro-inflammatory genes in BV2 microglia (Rayan et 
al. 2011). The present study also showed that costunolide treatment induces 
PPARγ expression in activated microglia post-TBI and attenuates the number 
of TNFα positive microglial cells in TBI rat brain. These results suggest that 
costunolide reduces TNFα positive microglia in TBI-induced rat brain 
possibly through PPARγ activation. 
 Another interesting observation found was that costunolide treatment 
markedly downregulated SphK1 expression in activated microglia post-TBI. 
SphK1, which is a key enzyme in sphingolipid metabolism pathway, has 
previously been shown to regulate NO production and expression of 
proinflammatory cytokines in activated microglia (Lin et al. 2011, Nayak et 
al. 2010). Though SphK1 is known to be transcriptionally regulated through 




between this enzyme and PPARγ in context of microglial inflammation needs 
to be examined further.  
It was also observed that costunolide treatment to activated microglial 
cells markedly reduced Runx1t1 expression both in vivo and in vitro. This 
finding is interesting as Runx1t1 appears to control microglial activation and 
proliferation in neuropathologies. However, the mechanism by which 
costunolide acts on Runx1t1 is not clear. One of the possible mechanisms by 
which costunolide exerts its inhibitory effect on Runx1t1 is by activating 
PPARγ.  
 Overall, this study demonstrated that costunolide modulates microglia-
mediated neuroinflammation in the rat brain post-TBI. The molecular docking 
predictions and experimental validations showed an effective binding of 
costunolide to PPARγ and identified the plausible mechanism of action of 
costunolide through PPARγ activation. Activation of PPARγ by costunolide 
suppresses the proinflammatory cytokines such as TNFα and the MAPK-
NFκB-mediated proinflammatory pathways in rat brains post-TBI. Thus 
costunolide mediated modulation of the PPARγ signaling in microglia may be 
considered for a potential therapeutic intervention of neurological disorders 






































One of the major inflammatory responses to neuropathologies including 
neurodegeneration and brain injury is activation of microglia, the resident 
immune cells of the CNS (Kaur et al. 1985, Ling & Wong 1993). Activated 
microglia undergo rapid proliferation, migrate to the site of injury or 
degeneration and clear cellular debris by phagocytosis. In humans with TBI, 
activated microglia were found to be distributed around the site of injury for 
several months (Loane & Byrnes 2010). Chronic activation of microglia leads 
to excessive production of proinflammatory cytokines and NO, which could 
contribute to neuroinflammation and subsequent neurodegeneration. Hence, 
controlling inflammatory response and  proliferation of microglia has been 
considered as an important aspect in treating neurodegenerative disorders 
including brain injury. Microglial activation is known to be influenced by 
various regulatory proteins including signaling molecules and transcription 
factors  (Dheen et al. 2002). Identifying these key molecules that control 
microglia-mediated neuroinflammation specifically, and the therapeutic agents 
including conventional synthetic drugs and herbal compounds that target these 
molecules could potentially help attenuate microglia-mediated 
neuroinflammation.  
  In this study, Runx1t1 was identified as one of the transcription 
factors, which control microglial proliferation by regulating cell cycle gene, 
Cdk4 in the brain injury. Runx1t1 has been shown to recruit HDACs for 
transcription repression and HDACs are known to control cell proliferation by 
regulating cell cycle genes. This study further demonstrated that HDAC 
inhibitor (HDACi) such as sodium butyrate mimics the loss of function of 




seems to be therapeutically important as microglial proliferation can be 
controlled by HDACi when they are chronically activated in pathological 
brain. However, HDACi may not target microglia specifically since the 
HDACs are ubiquitous enzymes (Fischer et al. 2010). 
 LAT2 another molecule studied, appears to have an important role in 
regulating microglial inflammatory response, since it has been shown to 
reduce NO production in the brain (Zielinska et al. 2011, Closs et al. 2006, 
Nicholson et al. 2001). The present study revealed that LAT2 expression was 
repressed in activated microglial cells, but induced by loss of function of 
Runx1t1 or HDACi treatment. Since ChIP assay revealed that Runx1t1 
directly binds to LAT2 gene promoter and recruits HDACs to transcriptionally 
repress LAT2, the loss of function of Runx1t1 or HDACi treatment may 
reduce NO production by activated microglia via upregulation of LAT2 
expression.  This study clearly demonstrates that downregulation of Runx1t1 
or inhibition of HDAC may suppress microglia-mediated neurotoxicity via 
inhibiting excessive NO production in pathological brain.  
Overall, this study demonstrated the expression pattern of Runx1t1 in 
the normal and activated microglial cells in vitro and in vivo including TBI 
and AD rat models and functional dynamics of Runx1t1 in regulating 
microglial proliferation and production of neurotoxic substance such as NO by 
activated microglia (See schematic diagram I).  
 In the second part of the study, costunolide, an anti-inflammatory 
herbal compound has been shown to inhibit microglial activation and its 
inflammatory response post-TBI by binding to its partner PPARγ, which is a 




transcription of inflammatory genes, such as TNF-α. It is suggested that 
costunolide inhibits microglial activation and subsequent neuroinflammation 
by binding and activating PPARγ receptor which in turn inhibts NFκB 
signaling pathway (See schematic diagram I).  
Treatment of TBI is difficult task since the drugs that used for 
treatment mainly alleviate neuronal death and promote neuronal survival but 
cannot control the inflammatory response of activated microglia (Hernandez-
Ontiveros et al. 2013). The present study demonstrates that costunolide, the 
herbal compound has anti-inflammatory properties and also exhibits specific 
inhibitory effects on the neurotoxicity of microglial cells, suggesting that 
costunolide has great potential therapeutically in treating microglia-mediated 









Schematic diagram I. Illustration summarizing the overall findings of the 
study: Microglial cells are activated by infection (LPS), injury (TBI), and 
degeneration (AD). Runx1t1 controls microglial activation and proliferation 
by recruiting HDACs. Runx1t1-HDAC complex controls microglial 
proliferation by regulating Cdk4 expression, and NO production  by repressing 
LAT2 expression in activated microglia. In addition, costunolide appears to 
inhibit the expression of Runx1t1 in activated microglia. Costunolide delivers 
its anti-inflammatory effects by binding to and activating PPARγ receptor, an 
inhibitor of NFκB signaling pathway. Costunolide induces MKP1 expression 
and inhibits NFκB signaling pathway possibly via inhibiting the MAPK 
pathway in activated microglia. Overall, costunolide inhibits microglia-
mediated neuroinflammation via interacting with PPARγ.  
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Neuropathologies including injury, infection, infarction and degeneration in 
human are often characterized by improper functioning of glial cells, leading 
to neuronal damage (Hirsch et al. 1998, Liu et al. 1997). Microglial cells can 
either have a protective or deleterious role in neurological diseases (Banati & 
Graeber 1994, Streit 2002). These cells generally function as macrophages by 
deterring pathological agents through phagocytosis. They have been shown to 
be detrimental to neurons in neurological diseases through production of nitric 
oxide, inflammatory cytokines and free radicals (Chao et al. 1992, Colton & 
Gilbert 1987). They are also involved in damaging the other glial cells such as 
oligodendrocytes, which are the most vulnerable to injuries causing 
myelination deficits (Peterson et al. 2002). However, mechanisms that 
underlie these processes are not fully explored and further research is clearly 
desirable to gain an in-depth knowledge of the “cross talks” between glial 
cells, and between them and neurons to understand their role in the 
progression of damage to the nervous system in various insults. This may lead 
to the development of new therapeutic strategies for ameliorating damage in 
brain insults.  
Dysregulation of microglial function was found to exacerbate several 
neuropathological conditions, indicating that microglia possess distinctive 
transcriptomic and epigenetic profiles in different neuropathologies (Parakalan 
et al. 2012, Ponomarev et al. 2013). In aging-associated neurodegenerative 
disorders such as Alzheimer’s disease, microglia exhibit a dystrophic 
phenotype, incapable of phagocytosing toxic β-amyloid peptides leading to 
neurodegeneration (Streit 2006). In neuropsychiatric disorders such as anxiety 
and depression, microglia were found to be in an activated state releasing 
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cytotoxic molecules as observed in the postmortem brain samples of 
individuals who committed suicide (Frick et al. 2013). Excessive microglial 
activation and ineffective phagocytosis of weaker synaptic connections during 
postnatal brain development by microglia are linked to the development of 
autism (Suzuki et al. 2013, Schafer et al. 2012). In stroke, microglia exhibit a 
dual phenotype: the neurotoxic M1 and neuroprotective M2 phenotypes 
(Thored et al. 2009). Microglial activation is considered as a biomarker for 
traumatic brain injury (TBI) (Hernandez-Ontiveros et al. 2013) which may be 
caused by motor vehicle and fall-related accidents and blasts. 
This present study mainly explored the mechanisms by which 
activation of microglia in response to inflammation and injury is regulated. 
Microglial activation and rapid proliferation in neuropathologies are controlled 
by various signaling molecules and transcription factors. In this study, 2 
transcription factors, i.e., Runx1t1 and PPARγ involved in controlling 
microglial activation and microglia-mediated neuroinflammation, have been 
identified. Runx1t1 recruits HDACs for transcriptional repression and 
promotes microglial activation by regulating their proliferation in 
neuropathological conditions, while PPARγ inhibits proinflammatory response 
of the activated microglia by modulating the MKP1 expression and NFκB 
signaling pathway. These findings would be helpful to develop new 
therapeutic strategies for treating patients with microglia-mediated 
neuroinflammation.  
This present study which clearly demonstrated that knockdown of 
Runx1t1 and inhibition of HDAC using a specific inhibitor (sodium butyrate) 
can interfere the microglia proliferation, is clinically significant since HDACs 
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are novel targets and several inhibitors of HDACs have already been tested in 
clinical trials for the treatment of various diseases (Tan et al. 2010, Piekarz & 
Bates 2004, Wagner et al. 2010). 
 Various HDAC inhibitors including sodium butyrate, valproic acid, 
trichostatin A (TSA), and suberoylanilide hydroxamic acid (SAHA) have been 
shown to inhibit microglial activation in vitro and in vivo (Xuan et al. 2012, 
Suuronen et al. 2003, Huuskonen et al. 2004). Screening of HDAC inhibitors, 
which selectively target individual HDAC and microglial activation in animal 
models of neurological diseases, would prove to be a better strategy to 
determine a specific drug, which combats with microglia-mediated 
inflammation. 
Further, this study can be greatly expanded with in vivo analysis using 
transgenic or knockout animal models. Especially, characterization of 
amoeboid, ramified and reactive microglia in Runx1t1 transgenic/knockout 
animal models would be helpful in understanding the role of Runx1t1 on 
microglial development and activation.  
  Several drugs have been shown to suppress inflammatory response of 
microglial cells. However, chronic use of these drugs may lead to side effects 
and medical consequences. Exploration of various herbal extracts would help 
limiting side effects in treating microglia-mediated neuroinflammation after 
brain injury, infection and other neurological disorders. Many herbal 
compounds with limited side effects have been used in treating microglia-
mediated neuroinflammation. We have previously shown that costunolide, a 
herbal compound has anti-inflammatory effect. In the current study, the 
mechanism of action of costunolide on microglial activation has been 
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explored. Costunolide delivers its inhibitory effects on the inflammatory 
response of microglia by binding and activating PPARγ receptor, a ligand 
activated transcription factor known to inhibit NFκB signaling pathway.  
The results obtained from this study provide 2 suggestions: 1. 
Costunolide can specifically suppress microglia activation in 
neuropathological conditions; 2. Identification of potential inhibitors for 
Runx1t1, and HDACs and agonists for PPARγ, possibly herbal compounds 
with inhibitory effects on microglial activation would help in combating with 
microglia-mediated neuroinflammation. 
 This study is clinically relevant and has great potential as further study 
would facilitate the development of innovative pharmacoepigenomic agents 
(such as HDACi) and herbal extracts (such as costunolide) with limited side 
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